#### CONSOLIDATED FINANCIAL STATEMENTS

Indiana University Health, Inc. and Subsidiaries Years Ended December 31, 2022 and 2021 With Report of Independent Auditors

Ernst & Young LLP



# **Consolidated Financial Statements**

Years Ended December 31, 2022 and 2021

## Contents

Report of Independent Auditors	1
Consolidated Financial Statements	
Consolidated Balance Sheets	3
Consolidated Statements of Operations and Changes in Net Assets	5
Consolidated Statements of Cash Flows	7
Notes to Consolidated Financial Statements	8



Ernst & Young LLP Suite 4000 111 Monument Circle Indianapolis, IN 46204 Tel: +1 317 681 7000 Fax: +1 317 681 7216

ey.com

## Report of Independent Auditors

The Board of Directors Indiana University Health, Inc. and Subsidiaries

#### **Opinion**

We have audited the consolidated financial statements of Indiana University Health, Inc. and Subsidiaries (Indiana University Health), which comprise the consolidated balance sheets as of December 31, 2022 and 2021, and the related consolidated statements of operations and changes in net assets and cash flows for the years then ended, and the related notes (collectively referred to as the financial statements).

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of Indiana University Health at December 31, 2022 and 2021, and the related changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

## **Basis for Opinion**

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Indiana University Health and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### **Responsibilities of Management for the Financial Statements**

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Indiana University Health's ability to continue as a going concern for one year after the date that the financial statements are issued.



#### **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free of material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether
  due to fraud or error, and design and perform audit procedures responsive to those risks.
   Such procedures include examining, on a test basis, evidence regarding the amounts and
  disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Indiana University Health's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Indiana University Health's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal-control-related matters that we identified during the audit.

Ernst + Young LLP

February 23, 2023

# Consolidated Balance Sheets

(Thousands of Dollars)

	December 31			
	2022			2021
Assets				
Current assets:				
Cash and cash equivalents	\$	342,828	\$	263,492
Short-term investments		22,916		9,136
Current portion of assets limited as to use		171,132		176,167
Patient accounts receivable		1,008,169		1,058,084
Other receivables		90,448		85,945
Prepaid expenses		84,151		84,268
Inventories		166,088		157,257
Total current assets		1,885,732		1,834,349
Assets limited as to use:				
Board-designated investment funds and other				
investments		5,632,873		6,877,092
Board-designated funds – community health		668,638		734,365
Board-designated funds – innovation		356,361		400,293
Donor-restricted investment funds		96,911		99,845
Total assets limited as to use, less current portion		6,754,783		8,111,595
Property and equipment:				
Cost of property and equipment in service		7,117,877		6,820,698
Less accumulated depreciation		(3,958,490)		(3,805,953)
		3,159,387		3,014,745
Construction-in-progress		366,757		131,237
Total property and equipment, net		3,526,144		3,145,982
Other assets:				
Interest in unconsolidated subsidiaries		17,028		15,380
Interests in net assets of unconsolidated foundations		15,737		15,820
Right-of-use assets		130,786		160,107
Interest rate swaps		86,200		32,839
Goodwill, intangibles, and other assets		374,425		381,021
Total other assets		624,176		605,167
Total assets	\$	12,790,835	\$	13,697,093

Continued on next page.

# Consolidated Balance Sheets (continued) (Thousands of Dollars)

	December 31			
	2022 2021			2021
Liabilities and net assets				
Current liabilities:				
Accounts payable and accrued expenses	\$	629,565	\$	926,209
Accrued salaries, wages, and related liabilities		434,560		426,780
Accrued health claims		49,050		59,667
Estimated third-party payer allowances		53,981		105,140
Current portion of lease liabilities		30,623		41,060
Current portion of long-term debt		54,027		56,718
Total current liabilities		1,251,806		1,615,574
Noncurrent liabilities:				
Long-term debt, less current portion		1,686,652		1,535,473
Interest rate swaps		10,360		7,606
Accrued medical malpractice claims		81,624		72,102
Lease liabilities, less current portion		110,773		130,868
Other		32,514		35,543
Total noncurrent liabilities		1,921,923		1,781,592
Total liabilities		3,173,729		3,397,166
Net assets:				
Indiana University Health		9,229,613		9,892,320
Noncontrolling interest in subsidiaries		257,633		266,242
Total without donor restrictions		9,487,246		10,158,562
With donor restrictions		129,860		141,365
Total net assets		9,617,106		10,299,927
Total liabilities and net assets	\$	12,790,835	\$	13,697,093

See accompanying notes to the consolidated financial statements.

# Consolidated Statements of Operations and Changes in Net Assets (Thousands of Dollars)

	Year Ended December 31			
	2022	2021		
Revenues:				
Patient service revenue	\$ 7,538,854	\$7,208,654		
Member premium revenue	289,385	281,361		
Other revenue	257,777	379,183		
Total operating revenues	8,086,016	7,869,198		
Expenses:				
Salaries, wages, and benefits	4,568,951	4,020,999		
Supplies, drugs, purchased services, and other	2,706,656	2,623,978		
Contribution to related entity	-	416,000		
Hospital assessment fee	206,632	185,979		
Health claims to providers	130,407	146,271		
Depreciation and amortization	303,451	279,433		
Interest	49,305	35,832		
Total operating expenses	7,965,402	7,708,492		
Operating income	120,614	160,706		
Nonoperating (loss) income:				
Investment (loss) income, net	(698,160)	882,845		
(Losses) gains on interest rate swaps, net	(2,399)	4,306		
Debt extinguishment and other	(7,309)	(34,554)		
Total nonoperating (loss) income	(707,868)	852,597		
Consolidated (deficit) excess of revenues over expenses	(587,254)	1,013,303		
Less amounts attributable to noncontrolling interest				
in subsidiaries	127,859	151,792		
(Deficit) excess of revenue over expenses attributable to				
University Health, Inc. and Subsidiaries	\$ (715,113)	\$ 861,511		

Continued on next page.

# Consolidated Statements of Operations and Changes in Net Assets (continued) (Thousands of Dollars)

	Year E	nde	d December 31	2022	)
	Total		Controlling	Non	controlling
Without donor restriction: Consolidated (deficit) excess of revenues over expenses	\$ (587,254)	\$	(715,113)	\$	127,859
Distributions to noncontrolling interests	(119,473)		_		(119,473)
Change in fair value of interest rate swaps designated as	53,006		53,006		-
Purchase of noncontrolling interests	(16,290)		_		(16,290)
Other	(1,305)		(600)		(705)
	 (671,316)		(662,707)		(8,609)
With donor restriction:					
Change in beneficial interest in net assets of foundations	(306)		(306)		_
Contributions	5,999		5,999		_
Investment return	(4,980)		(4,980)		_
Change in split interest agreements	(2,257)		(2,257)		-
Net assets released from restrictions	(7,537)		(7,537)		_
Other	 (2,424)		(2,424)		
	(11,505)		(11,505)		
Decrease in net assets	(682,821)		(674,212)		(8,609)
Net assets at beginning of period	10,299,927		10,033,685		266,242
Net assets at beginning or period  Net assets at end of period	\$ 9,617,106	\$	9,359,473	\$	257,633
	 Year E	nde	d December 31 Controlling		controlling
Without donor restriction:					<u> </u>
Consolidated excess of revenues over expenses	\$ 1,013,303	\$	861,511	\$	151,792
Distributions to noncontrolling interests	(147,008)		_		(147,008)
Change in fair value of interest rate swaps designated as	18,207		18,207		_
Purchase of noncontrolling interests	(36,804)		(19,512)		(17,292)
Other	 17,050		(1,241)		18,291
	 864,748		858,965		5,783
With donor restriction:					
Change in beneficial interest in net assets of foundations	(6,576)		(6,576)		-
Contributions	12,635		12,635		-
Investment return	6,342		6,342		_
invocation rotain					
Change in split interest agreements	1,768		1,768		-
	1,768 (4,303)		(4,303)		- -
Change in split interest agreements	1,768				- - -
Change in split interest agreements Net assets released from restrictions	1,768 (4,303)		(4,303)		- - - -
Change in split interest agreements Net assets released from restrictions Other	1,768 (4,303) (459) 9,407		(4,303) (459) 9,407		- - - - 5 783
Change in split interest agreements Net assets released from restrictions	 1,768 (4,303) (459)		(4,303) (459)		5,783 260,459

See accompanying notes to the consolidated financial statements.

# Consolidated Statements of Cash Flows (Thousands of Dollars)

		Year Ended December 31		
Cocrease  increase in net assets   \$ (682,821) \$ 874,155     Adjustments to reconcile increase in net assets to net cash provided by operating activities:   Change in fair value of interest rate swaps   (50,607)   (22,403)     Gain in unconsolidated subsidiaries   (1,498)   (1,498)     Depreciation and amortization   303,451   279,433     Contributions and investment return with donor restriction   1,544   (14,169)     Distributions to noncontrolling interests   1,282,796   (674,434)     Nat changes in operating assets and liabilities:   1,282,796   (674,434)     Nat changes in operating assets and liabilities:   2,282,796   (674,434)     Nat changes in operating assets and liabilities   49,915   (169,598)     Accounts payable, accrued liabilities, and other liabilities   3,00,768   90,527     Accrued salaries, wages, and related liabilities   7,780   (8,377)     Cash and cash equivalents   685,093   529,884     Net cash provided by operating activities   685,093   529,884     Investing activities   (682,209)   (472,497)     Financing activities   (682,209)   (472,497)     Contributions and investment return with donor restrictions   (1,544)   (1,69,305)     Cartinotion of one payable under lines of credit   (95,000)   (49,900)     Contributions and investment return with donor restrictions   (1,544)   (1,69,305)     Cartinotion of interest rate swaps   (1,6,84)   (1,6,84)     Purchase of noncontrolling interests   (1,6,84)   (1,6,84)     Purchase of noncontrolling interests   (1,6,84)   (1,9,305)     Cash and cash equivalents at beginning of period   (2,9,302)   (2,9,302)			2022	2021
Cocrease  increase in net assets   \$ (682,821) \$ 874,155     Adjustments to reconcile increase in net assets to net cash provided by operating activities:   Change in fair value of interest rate swaps   (50,607)   (22,403)     Gain in unconsolidated subsidiaries   (1,802)   (1,498)     Depreciation and amortization   303,451   279,433     Contributions and investment return with donor restriction   1,544   (14,169)     Distributions to noncontrolling interests   1,282,796   (674,434)     Nat changes in operating assets and liabilities:   1,282,796   (674,434)     Nat changes in operating assets and liabilities;   49,915   (169,598)     Accounts payable, accrued liabilities, and other liabilities   7,780   (8,377)     Accrued salaries, wages, and related liabilities   7,780   (8,377)     Estimated third-party payer allowances   (51,159)   (50,621)     Other assets   7,291   79,861     Net cash provided by operating activities   (882,209)   (472,497)     Financing activities   (882,209)   (472,497)     Financing activities   (882,209)   (472,497)     Financing activities   (95,000)   - (472,497)     Financing activities   (1,544)   (1,69,305)     Contributions and investment return with donor restrictions   (1,544)   (1,69,305)     Contributions and investment return with donor restrictions   (1,544)   (1,69,305)     Contributions and investment return with donor restrictions   (1,544)   (1,69,305)     Contributions and investment return with donor restrictions   (1,544)   (1,69,305)     Contributions and investment return with donor restrictions   (1,544)   (1,69,305)     Contributions to noncontrolling interests   (1,6,290)   (4,8,958)     Contributions to noncontrolling interests   (1,6,844)   (1,6,844)   (1,6,844)     Contributions of noncontrolling interests   (1,6,844)	Operating activities			
Adjustments to reconcile increase in net assets to net cash provided by operating activities:  Change in fair value of interest rate swaps  Depreciation and amortization  Contributions and investment return with donor restriction  Distributions to noncontrolling interests  Distributions to noncontrolling interests  Net changes in operating assets and liabilities:  Patient accounts receivable  Accounts payable, accured liabilities, and other liabilities  Patient accounts receivable  Accounts payable, accured liabilities, and other liabilities  Repayments of property and equipment, net of disposals  Entresting activities  Financing activities  Financi		\$	(682 821) \$	874 155
Descripting activities:	,	*	(002,021) +	01 1,200
Change in fair value of interest rate swaps         (50,607)         (22,403)           Gain in unconsolidated subsidiaries         (1,802)         (1,498)           Depreciation and amortization         303,451         279,433           Contributions and investment return with donor restriction         1,544         (14,169)           Distributions to noncontrolling interests         119,473         147,008           Assets limited as to use         1,282,796         (674,434)           Net changes in operating assets and liabilities:         49,915         (169,598)           Accounts payable, accrued liabilities, and other liabilities         300,768)         90,527           Accrued salaries, wages, and related liabilities         7,780         (8,377)           Estimated third-party payer allowances         (51,159)         (50,621)           Other assets         7,291         79,861           Net cash provided by operating activities         685,093         529,884           Investing activities           Purchase of property and equipment, net of disposals         (682,209)         (472,497)           Net cash used in investing activities         315,000         -           Proceeds from notes payable under lines of credit         (95,000)         -           Repayments of notes payable under line	·			
Gain in unconsolidated subsidiaries         (1,802)         (1,498)           Depreciation and amortization         303,451         279,433           Contributions and investment return with donor restriction         1,544         (14,169)           Distributions to noncontrolling interests         119,473         147,008           Assets limited as to use         1,282,796         (674,434)           Net changes in operating assets and liabilities:         80,0158         1,69,598           Accounts payable, accrued liabilities, and other liabilities         (300,768)         90,527           Accounts payable, accrued liabilities, and other liabilities         7,780         (8,377)           Accounts payable, accrued liabilities, and other liabilities         7,780         (8,377)           Accounts payable, accrued liabilities, and other liabilities         7,780         (8,377)           Accounts payable, accrued liabilities, and other liabilities         7,780         (8,377)           Accounts payable, accrued liabilities, and other liabilities         685,093         52,884           Accounts payable under lines of credit         685,093         252,884           Investing activities         (682,209)         (472,497)           Net cash provided by operating activities         315,000         -           Proparting activities			(50,607)	(22 403)
Depreciation and amortization         303,451         279,433           Contributions and investment return with donor restriction         1,544         (14,169)           Distributions to noncontrolling interests         119,473         147,008           Assets limited as to use         1,282,796         (674,434)           Net changes in operating assets and liabilities:         8,995         (169,598)           Patient accounts payable, accrued liabilities, and other liabilities         300,768         90,527           Accrued salaries, wages, and related liabilities         7,780         (8,377)           Estimated third-party payer allowances         (51,159)         (50,621)           Other assets         7,291         79,861           Net cash provided by operating activities         685,093         529,884           Investing activities         (682,209)         (472,497)           Purchase of property and equipment, net of disposals         (682,209)         (472,497)           Net cash used in investing activities         (682,209)         (472,497)           Financing activities         315,000         -           Proceeds from notes payable under lines of credit         (95,000)         -           Repayments of notes payable under lines of credit         (95,000)         -           Is	- · · · · · · · · · · · · · · · · · · ·			
Contributions and investment return with donor restriction         1,544         (14,169)           Distributions to noncontrolling interests         119,473         147,008           Assets limited as to use         1,282,796         (674,334)           Net changes in operating assets and liabilities:         49,915         (169,598)           Patient accounts receivable         49,915         (8,377)           Accounts payable, accrued liabilities, and other liabilities         (300,768)         90,527           Accoude salaries, wages, and related liabilities         7,780         (8,377)           Estimated third-party payer allowances         (51,159)         (50,621)           Other assets         7,291         79,861           Net cash provided by operating activities         685,093         529,884           Investing activities         (682,209)         (472,497)           Purchase of property and equipment, net of disposals         (682,209)         (472,497)           Net cash used in investing activities         (682,209)         (472,497)           Proceeds from notes payable under lines of credit         (95,000)         -           Repayments of notes payable under lines of credit         (95,000)         -           Repayments of notes payable under lines of credit         (1,544)         (1,61,604)			• • • • • • • • • • • • • • • • • • • •	* ' '
Distributions to noncontrolling interests         119,473         147,008           Assets limited as to use         1,282,796         (674,434)           Net changes in operating assets and liabilities:         849,915         (169,598)           Patient accounts receivable         49,915         (169,598)           Accounts payable, accrued liabilities, and other liabilities         (300,768)         90,527           Accrued salaries, wages, and related liabilities         (51,159)         (50,621)           Other assets         7,291         79,861           Net cash provided by operating activities         685,093         529,884           Investing activities         (682,209)         (472,497)           Purchase of property and equipment, net of disposals         (682,209)         (472,497)           Net cash used in investing activities         (682,209)         (472,497)           Financing activities         (682,209)         (472,497)           Proceeds from notes payable under lines of credit         (95,000)         -           Repayments of notes payable under lines of credit         (95,000)         -           Issuance of long-term debt, net of discount         (1,544)         14,769           Repayments on long-term debt, net of discount         (1,544)         14,069           Purc	•			
Assets limited as to use         1,282,796         (674,434)           Net changes in operating assets and liabilities:         49,915         (169,588)           Patient accounts receivable         49,915         (169,588)           Accounds spayable, accrued liabilities, and other liabilities         (300,768)         90,527           Accrued salaries, wages, and related liabilities         7,780         (8,377)           Estimated third-party payer allowances         (51,159)         (50,621)           Other assets         7,921         79,861           Net cash provided by operating activities         685,093         529,884           Investing activities         (682,209)         (472,497)           Purchase of property and equipment, net of disposals         (682,209)         (472,497)           Net cash used in investing activities         (682,209)         (472,497)           Purchase of property and equipment, net of disposals         (682,209)         (472,497)           Net cash used in investing activities         (682,209)         (472,497)           Purchase of property and equipment, net of disposals         (682,209)         (472,497)           Purchase of property and equipment insectifications of credit         315,000         -           Repayments of notes payable under lines of credit         9,000			•	
Net changes in operating assets and liabilities:         49,915         (169,598)           Patient accounts receivable         49,915         (169,598)           Accounts payable, accrued liabilities, and other liabilities         (300,768)         90,527           Accrued salaries, wages, and related liabilities         7,780         (8,377)           Estimated third-party payer allowances         (51,159)         (50,621)           Other assets         7,291         79,861           Net cash provided by operating activities         685,093         529,884           Investing activities         (682,209)         (472,497)           Net cash used in investing activities         (682,209)         (472,497)           Net cash used in investing activities         (682,209)         (472,497)           Proceeds from notes payable under lines of credit         315,000         -           Repayments of notes payable under lines of credit         (95,000)         -           Issuance of long-term debt, net of discount         (95,000)         -           Contributions and investment return with donor restrictions         (1,544)         14,169           Repayments on long-term debt, net of discount         (71,512)         (16,684)           Purchase of noncontrolling interests         (16,290)         (48,958)	<u> </u>			
Patient accounts receivable         49,915         (169,598)           Accounts payable, accrued liabilities, and other liabilities         (300,768)         90,527           Accrued salaries, wages, and related liabilities         (51,159)         (50,621)           Other assets         (51,159)         (50,621)           Other assets         7,291         79,861           Net cash provided by operating activities         685,093         529,884           Investing activities           Purchase of property and equipment, net of disposals         (682,209)         (472,497)           Net cash used in investing activities         (682,209)         (472,497)           Purchase of property and equipment, net of disposals         (682,209)         (472,497)           Net cash used in investing activities         315,000         -           Proceeds from notes payable under lines of credit         (95,000)         -           Repayments of notes payable under lines of credit         (95,000)         -           Issuance of long-term debt, net of discount         (71,512)         (16,000)           Contributions and investment return with donor restrictions         (1,544)         14,169           Repayments on long-term debt, net of discount         (71,512)         (16,684)           Purchase of noncontrolli			_,,	(01 1, 10 1)
Accounts payable, accrued liabilities, and other liabilities         (300,768)         90,527           Accrued salaries, wages, and related liabilities         7,780         (8,377)           Estimated third-party payer allowances         (51,159)         (50,621)           Other assets         7,291         79,861           Net cash provided by operating activities         685,093         529,884           Investing activities         (682,209)         (472,497)           Net cash used in investing activities         (682,209)         (472,497)           Net cash used in investing activities         315,000         -           Proceeds from notes payable under lines of credit         (95,000)         -           Repayments of notes payable under lines of credit         (95,000)         -           Repayments of notes payable under lines of credit         (95,000)         -           Issuance of long-term debt, net of discount         -         404,791           Contributions and investment return with donor restrictions         (1,544)         14,169           Repayments on long-term debt, net of discount         (71,512)         (16,9305)           Termination of interest rate swaps         -         (16,684)           Purchase of noncontrolling interests         (119,473)         (147,008)			49.915	(169.598)
Accrued salaries, wages, and related liabilities         7,780         (8,377)           Estimated third-party payer allowances         (51,159)         (50,621)           Other assets         7,291         79,861           Net cash provided by operating activities         685,093         529,884           Investing activities         (682,209)         (472,497)           Purchase of property and equipment, net of disposals         (682,209)         (472,497)           Net cash used in investing activities         (682,209)         (472,497)           Financing activities         315,000         -           Proceeds from notes payable under lines of credit         (95,000)         -           Repayments of notes payable under lines of credit         (95,000)         -           Issuance of long-term debt, net of discount         (71,512)         (169,305)           Contributions and investment return with donor restrictions         (1,544)         14,169           Repayments on long-term debt, net of discount         (71,512)         (16,684)           Purchase of noncontrolling interests         (16,290)         (48,958)           Distributions to noncontrolling interests         (119,473)         (147,008)           Net as provided by financing activities         11,181         37,005           N			•	
Estimated third-party payer allowances Other assets Other as			• • •	
Other assets         7,291         79,861           Net cash provided by operating activities         685,093         529,884           Investing activities           Purchase of property and equipment, net of disposals         (682,209)         (472,497)           Net cash used in investing activities         (682,209)         (472,497)           Financing activities           Proceeds from notes payable under lines of credit         315,000         -           Repayments of notes payable under lines of credit         (95,000)         -           Repayments of notes payable under lines of credit         (95,000)         -           Issuance of long-term debt, net of discount         (1,544)         14,169           Contributions and investment return with donor restrictions         (1,544)         14,169           Repayments on long-term debt, net of discount         (71,512)         (166,804)           Purchase of noncontrolling interests at exwaps         -         (16,684)           Purchase of noncontrolling interests         (119,473)         (147,008)           Net cash provided by financing activities         11,181         37,005           Net increase in cash and cash equivalents         14,065         94,392           Cash and cash equivalents at end of period         427,224         <	_			
Net cash provided by operating activities   Session				
Purchase of property and equipment, net of disposals Net cash used in investing activities  Financing activities  Proceeds from notes payable under lines of credit Repayments of long-term debt, net of discount Contributions and investment return with donor restrictions Repayments on long-term debt, net of discount Repayments of long-term debt, net of discount Repayments of long-term debt, net of discount Repayments of long-term debt, 14,169				
Purchase of property and equipment, net of disposals Net cash used in investing activities  Financing activities  Proceeds from notes payable under lines of credit Repayments of long-term debt, net of discount Contributions and investment return with donor restrictions Repayments on long-term debt, net of discount Repayments of long-term debt, net of discount Repayments of long-term debt, net of discount Repayments of long-term debt, 14,169	Investing activities			
Net cash used in investing activities  Financing activities  Proceeds from notes payable under lines of credit Repayments of long-term debt, net of discount Contributions and investment return with donor restrictions Repayments on long-term debt, net of discount Termination of interest rate swaps Termination of interest	_		(692 200)	(472.407)
Financing activities Proceeds from notes payable under lines of credit Repayments of notes payable under lines of credit Repayments of notes payable under lines of credit Repayments of long-term debt, net of discount Contributions and investment return with donor restrictions Repayments on long-term debt, net of discount Termination of interest rate swaps Repayments on long-term debt, net of discount Termination of interest rate swaps Purchase of noncontrolling interests (16,290) Repayments on noncontrolling interests (119,473) Repayments on oncontrolling interests (149,085) Repayments on oncontrolling interests (149,085) Repayments on oncontrolling interests (149,085) Repayments on long-term debt, net of discount (147,086) Repayments on long-term debt, net of discount (147,080) Repayments on long-term debt, net of discount (147,081) Repayments on long-term debt, net of discount (147,082) Repayments on long-term debt, net of discount (146,884) Repayments on long-term debt, ne				
Proceeds from notes payable under lines of credit Repayments of long-term debt, net of discount Contributions and investment return with donor restrictions Repayments on long-term debt, net of discount (71,544) Repayments on long-term debt, net of discount (71,512) (169,305) Termination of interest rate swaps (16,290) (48,958) Distributions to noncontrolling interests (119,473) Ret cash provided by financing activities (119,473) Ret increase in cash and cash equivalents Cash and cash equivalents at beginning of period A27,224 332,832 Cash and cash equivalents at end of period A27,224 Reconciliation of cash and cash equivalents to the consolidated balance sheets Cash and cash equivalents Cash and cash equivalents Cash and cash equivalents Sa42,828 Sa63,492 Cash and cash equivalents included in assets limited as to use  98,461 163,732				
Repayments of notes payable under lines of credit Issuance of long-term debt, net of discount Contributions and investment return with donor restrictions Repayments on long-term debt, net of discount Repayments on long-term debt, net of discount Termination of interest rate swaps Termination of interest rate swaps Purchase of noncontrolling interests Distributions to noncontrolling interests (16,290) Repayments on noncontrolling interests (119,473) Recash provided by financing activities  Net increase in cash and cash equivalents Cash and cash equivalents at beginning of period Reconciliation of cash and cash equivalents to the consolidated balance sheets Cash and cash equivalents  Cash and cash equivalents  Cash and cash equivalents  \$ 342,828 \$ 263,492 Cash and cash equivalents included in assets limited as to use  \$ 98,461 163,732	-			
Issuance of long-term debt, net of discount  Contributions and investment return with donor restrictions  Repayments on long-term debt, net of discount  Termination of interest rate swaps  Purchase of noncontrolling interests  Distributions to noncontrolling interests  Cash and cash equivalents at beginning of period  Reconciliation of cash and cash equivalents to the consolidated balance sheets  Cash and cash equivalents  Cash and cash equivalents included in assets limited as to use				_
Contributions and investment return with donor restrictions  Repayments on long-term debt, net of discount  Termination of interest rate swaps Purchase of noncontrolling interests Distributions to noncontrolling interests (16,290) (48,958) Distributions to noncontrolling interests (119,473) (147,008) Net cash provided by financing activities  Net increase in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period  Reconciliation of cash and cash equivalents to the consolidated balance sheets Cash and cash equivalents  Cash and cash equivalents  Cash and cash equivalents  \$ 342,828 \$ 263,492 Cash and cash equivalents included in assets limited as to use	Repayments of notes payable under lines of credit		(95,000)	-
Repayments on long-term debt, net of discount Termination of interest rate swaps Purchase of noncontrolling interests Distributions to noncontrolling interests Net cash provided by financing activities  Net increase in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period  Reconciliation of cash and cash equivalents to the consolidated balance sheets Cash and cash equivalents Cash and cash equivalents Cash and cash equivalents  Reconciliation of cash and cash equivalents to the consolidated balance sheets Cash and cash equivalents Cash and cash equivalents  Cash and cash equivalents  \$ 342,828 \$ 263,492 Cash and cash equivalents included in assets limited as to use	_		_	
Termination of interest rate swaps Purchase of noncontrolling interests Distributions to noncontrolling interests (16,290) (48,958) Distributions to noncontrolling interests (119,473) (147,008) Net cash provided by financing activities 11,181 37,005  Net increase in cash and cash equivalents Cash and cash equivalents at beginning of period 427,224 332,832 Cash and cash equivalents at end of period 427,224 332,832  Reconciliation of cash and cash equivalents to the consolidated balance sheets Cash and cash equivalents Cash and cash equivalents  Cash and cash equivalents  \$ 342,828 \$ 263,492 Cash and cash equivalents included in assets limited as to use  98,461 163,732			` ' '	
Purchase of noncontrolling interests Distributions to noncontrolling interests Net cash provided by financing activities  Net increase in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period  Reconciliation of cash and cash equivalents to the consolidated balance sheets Cash and cash equivalents Cash and cash equivalents Cash and cash equivalents  Reconciliation of cash and cash equivalents to the consolidated balance sheets Cash and cash equivalents Cash and cash equivalents  Satz, 224  16,290  147,008  11,181  37,005  Purchase in cash and cash equivalents  427,224  332,832  Reconciliation of cash and cash equivalents to the consolidated balance sheets Cash and cash equivalents  Satz, 263,492  Cash and cash equivalents included in assets limited as to use	Repayments on long-term debt, net of discount		(71,512)	, ,
Distributions to noncontrolling interests Net cash provided by financing activities  11,181  37,005  Net increase in cash and cash equivalents Cash and cash equivalents at beginning of period 427,224  332,832  Cash and cash equivalents at end of period  Reconciliation of cash and cash equivalents to the consolidated balance sheets  Cash and cash equivalents  Cash and cash equivalents  Cash and cash equivalents  \$342,828 \$ 263,492  Cash and cash equivalents included in assets limited as to use	Termination of interest rate swaps		-	(16,684)
Net cash provided by financing activities  11,181 37,005  Net increase in cash and cash equivalents Cash and cash equivalents at beginning of period 427,224 332,832  Cash and cash equivalents at end of period \$ 441,289 \$ 427,224  Reconciliation of cash and cash equivalents to the consolidated balance sheets  Cash and cash equivalents Cash and cash equivalents  \$ 342,828 \$ 263,492  Cash and cash equivalents included in assets limited as to use  98,461 163,732	Purchase of noncontrolling interests		• • • •	
Net increase in cash and cash equivalents  Cash and cash equivalents at beginning of period  Cash and cash equivalents at end of period  Reconciliation of cash and cash equivalents to the consolidated balance sheets  Cash and cash equivalents  Cash and cash equivalents  Cash and cash equivalents  \$ 342,828 \$ 263,492  Cash and cash equivalents included in assets limited as to use	Distributions to noncontrolling interests		(119,473)	(147,008)
Cash and cash equivalents at beginning of period \$\frac{427,224}{\$\frac{332,832}{\$\frac{234}{\$\frac{24}{\frac{24}{\$\frac{24}{\$\frac{24}{\$\frac{24}{\$\frac{24}{\$\frac{24}{\frac{24}{\$\frac{24}{\$\frac{24}{\$\frac{24}{\$\frac{24}{\$\frac{24}{\$\frac{24}{\$\frac{24}{\$\frac{24}{\$\frac{24}{\$\frac{24}{\$2	Net cash provided by financing activities		11,181	37,005
Cash and cash equivalents at end of period \$ 441,289 \$ 427,224  Reconciliation of cash and cash equivalents to the consolidated balance sheets Cash and cash equivalents \$ 342,828 \$ 263,492 Cash and cash equivalents included in assets limited as to use 98,461 163,732	Net increase in cash and cash equivalents		14,065	94,392
Reconciliation of cash and cash equivalents to the consolidated balance sheets Cash and cash equivalents Cash and cash equivalents included in assets limited as to use  \$ 342,828 \$ 263,492	Cash and cash equivalents at beginning of period		427,224	332,832
consolidated balance sheetsCash and cash equivalents\$ 342,828 \$ 263,492Cash and cash equivalents included in assets limited as to use98,461 163,732	Cash and cash equivalents at end of period	\$	441,289 \$	427,224
consolidated balance sheetsCash and cash equivalents\$ 342,828 \$ 263,492Cash and cash equivalents included in assets limited as to use98,461 163,732	Reconciliation of cash and cash equivalents to the			
Cash and cash equivalents \$ 342,828 \$ 263,492 Cash and cash equivalents included in assets limited as to use \$ 98,461 163,732	•			
Cash and cash equivalents included in assets limited as to use 98,461 163,732		\$	342.828 \$	263.492
	·	•	•	
	Cash and cash equivalents at end of period	\$		

See accompanying notes to the consolidated financial statements.

# Notes to Consolidated Financial Statements (Thousands of Dollars)

December 31, 2022

#### **Enterprise Vision:**

We will lead the transformation of healthcare through quality, innovation & education, and make Indiana one of the nation's healthiest states.

#### Promise:

The Best Care, Designed for You.

#### Values:

Purpose. Excellence. Compassion. Team.

#### 1. Organization and Nature of Operations

#### **History and Organization**

Indiana University Health, Inc. (Indiana University Health) and Subsidiaries operate as an integrated health care delivery system, which includes an academic health center affiliated with Indiana University, providing health care services in the State of Indiana. Health care services provided by Indiana University Health and its subsidiaries (hereinafter referred to as the Indiana University Health System) include acute, nonacute, tertiary, and quaternary care services on an inpatient, outpatient, and emergency basis; medical education and research; health care diagnostic and treatment services for individuals and families in physician clinics and physician-group practices; personal and home health care; and medical management services. The Indiana University Health System is also involved in philanthropic activities through affiliated foundations.

Indiana University Health was formed as an Indiana nonprofit corporation through a consolidation, as of January 1, 1997, under the terms of a Definitive Health Care Resources Consolidation Agreement, as amended (the Consolidation Agreement), and certain other related agreements by and between the Trustees of Indiana University and Methodist Health Group, Inc. (formerly known as Methodist Hospital of Indiana, Inc.). The facilities and operations of Indiana University Health University Hospital (University Hospital), Riley Hospital for Children at Indiana University Health (Riley Hospital), and Indiana University Health Methodist Hospital (Methodist Hospital) (collectively, the Downtown Indianapolis Hospitals of the Academic Health Center) were merged and consolidated to form a single corporate entity,

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 1. Organization and Nature of Operations (continued)

which was then licensed as a single acute care hospital and operates as an academic health center. Members of the Board of Directors (the Board) of Indiana University Health are selected by its two classes of members: the Methodist Class (members of which are members of Methodist Health Group, Inc.) and the University Class (members of which are the individuals who are the Trustees of Indiana University).

The Consolidation Agreement requires Indiana University Health to fund the salaries and related employee benefit costs for medical doctor interns and residents of the Indiana University School of Medicine (the School of Medicine) who provide services at the Indiana University Health System's facilities. Management annually reviews and determines the level of support to provide to the School of Medicine for these programs and the number of internships and residencies to be supported. The Consolidation Agreement also requires Indiana University Health to provide additional support to the School of Medicine to recognize, as a result of the consolidation, the enhanced and increased level of services being provided, including services to the medically indigent through medical education and research.

#### **Nature of Operations**

The Indiana University Health System operates as an integrated health care delivery system comprising nonprofit and for-profit entities, with coordinated activities and policies designed to meet the mission of the Indiana University Health System. The principal operating activities of the Indiana University Health System are conducted at majority-owned or controlled subsidiaries and consist of the following as of December 31, 2022:

#### Inpatient, Outpatient, Emergency Health Care Services, Medical Education, and Research

Downtown Indianapolis Hospitals of the Academic Health Center – Consist of three acute, tertiary, quaternary care, and diagnostic facilities, licensed as a single hospital, which constitutes the principal hospital activities of the academic health center and whose operations are located in the downtown area of Indianapolis, Indiana. These three hospitals, Methodist Hospital, University Hospital, and Riley Hospital, are located on or near the campus of Indiana University-Purdue University Indianapolis and the School of Medicine.

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 1. Organization and Nature of Operations (continued)

Indianapolis Suburban Facilities – Consist of three acute care hospitals, a critical access hospital, and an acute care rehabilitation hospital located in the western and northern suburban areas of metropolitan Indianapolis, Indiana. Principal hospital subsidiaries include Indiana University Health North Hospital, Inc.; Indiana University Health West Hospital, Inc.; Indiana University Health Saxony Hospital; Indiana University Health Tipton Hospital, Inc.; and Rehabilitation Hospital of Indiana, Inc.

West Central Indiana Facilities – Consist of one acute care hospital, and two critical access hospitals located in Lafayette; Monticello; and Frankfort, Indiana. Principal hospital subsidiaries include Indiana University Health Arnett, Inc.; Indiana University Health White Memorial Hospital, Inc.; and Indiana University Health Frankfort, Inc.

East Central Indiana Facilities – Consist of one acute care hospital, and two critical access hospitals located in Muncie; Hartford City; and Portland, Indiana. Principal hospital subsidiaries include Indiana University Health Ball Memorial Hospital, Inc. and subsidiaries, including Indiana University Health Blackford Hospital, Inc.; and Indiana University Health Jay, Inc.

South Central Indiana Facilities – Consist of one acute care hospital, and two critical access hospitals located in Bloomington; Bedford; and Paoli, Indiana. Principal hospital subsidiaries include Indiana University Health Bloomington, Inc. and subsidiaries; Indiana University Health Bedford, Inc.; and Indiana University Health Paoli, Inc.

#### Physician Clinics and Group Practice Health Care Services

Physician Operations – Consist of physician offices and physician-group practices and clinics. Principal subsidiaries or divisions include Indiana University Health Physicians, an organization with locations primarily in Indianapolis, Indiana; Indiana University Health Arnett Physicians; Indiana University Health Ball Memorial Physicians, Inc.; Indiana University Health Fort Wayne; and Indiana University Health Southern Indiana Physicians, Inc.

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 1. Organization and Nature of Operations (continued)

#### Personal and Home Health Care Services

Ambulatory Care – Consists of personal and home health care services, occupational health services, outpatient oncology services, outpatient surgery centers, and urgent care centers that are located throughout the State of Indiana. Principal divisions or subsidiaries include Indiana University Health Home Care, Indiana University Occupational Health Centers, Workplace Health Services, Indiana University Health Central Indiana Cancer Centers, Indiana University Health Morgan, surgery center joint ventures, and urgent care centers.

### **Medical Management Services**

Medical Risk – Consists of the medical management of health care services of members whose health care coverage is provided by the managed care networks of the Indiana University Health System and third parties. Includes health maintenance organizations and other insurance-related organizations that provide health plan services to fully insured and self-insured members residing in Indiana. Insurance offerings include commercial group products (fully insured and self-insured) and Medicare Advantage products. Beginning January 1, 2022, the Indiana University Health System also participates in the medical management of Medicare fee-for-service members through a direct contracting entity participant agreement. Through December 31, 2021, the Indiana University Health System participated in a NextGen Accountable Care Organization contract with the Centers for Medicare & Medicaid Services (CMS) for these members.

#### **Philanthropic Activities**

**Foundations** – Consist of two entities that aid in carrying out the mission of the Indiana University Health System: Indiana University Health Foundation, Inc. (Indiana University Health Foundation) and RHI Foundation, Inc.

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 2. Significant Events

#### **Coronavirus Pandemic**

The global viral outbreak caused by coronavirus disease 2019 (COVID-19) resulted in a national public health emergency. There have been resulting effects in the economy generally and the health care industry specifically that have and will continue to impact Indiana University Health's financial condition. During 2022 and 2021, the U.S. government issued legislation to authorize funding to healthcare providers to prevent, prepare for, and respond to COVID-19, and to reimburse the recipient for healthcare-related expenses and lost revenues attributable to COVID-19. Additionally, funds were available to reimburse providers for COVID-19-related treatment of uninsured patients. Indiana University Health has recognized revenue from payments received under these pieces of legislation when related conditions have been substantially met.

For the year ended December 31, 2022, Indiana University Health recognized \$17,183 of stimulus funds as other revenue from provisions of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) and the American Rescue Plan Act of 2021 (ARP). For the year ended December 31, 2021, Indiana University Health recognized a total of \$107,924 in stimulus funds.

In April 2020, Indiana University Health received \$348,448 from CMS as an advance payment under the Accelerated and Advance Payment Program, which was expanded through provisions of the CARES Act to ensure providers and suppliers have the resources needed to combat COVID-19. The recoupment period for Indiana University Health ended mid-October 2022. At the end of the recoupment period, all funds had been repaid and no interest related to the advanced payments was owed. As of December 31, 2021, CMS had recouped \$143,286, and the remaining portion of the contract liability of \$205,162, as of December 31, 2021, was included within accounts payable and accrued expenses on the consolidated balance sheet.

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 3. Community Benefit

Indiana University Health provides healthcare services and free or discounted care through various strategies (including population health management and community health) that are designed to enhance the health of communities served by Indiana University Health affiliate hospitals, improve the health of patients experiencing health inequities, and foster medical education and research through its affiliation with the School of Medicine. In addition, Indiana University Health provides services to patients and communities that have limited access to healthcare services and are underserved, including those persons who are uninsured or underinsured. Healthcare services to patients who qualify for government programs, such as Medicare and Medicaid, are also considered part of Indiana University Health's benefit provided to the community since a substantial portion of such services is reimbursed at amounts less than cost.

Indiana University Health also provides education for healthcare providers, including support to the School of Medicine; education and training for allied health professionals; chaplaincy programs that support patients' medical, spiritual, and emotional needs; programs to enhance health and well-being in the community, including neighborhood revitalization, community health clinics, and food access programs; charity, equality, and justice programs, including education programs available to independent health providers: and chronic disease and chronic disease management programs such as Jump IN for Healthy Kids and iHEART collaborative; other medical research, including support to the Indiana University Health Values Children's Fund; and the fostering of an internal community of trust, respect, and empowerment.

All affiliate hospitals in the healthcare system, along with community stakeholders, identified and prioritized significant needs unique to the communities they serve including improving access to healthcare services; aging population and needs of seniors; behavioral health (includes drug and substance abuse, as well as mental health); chronic disease and chronic disease management; education, workforce training, and unemployment; maternal and infant health and child well-being; smoking, tobacco use, and exposure to secondhand smoke; and other social determinants of health. These needs are identified through the community health needs assessment process. Some of these needs are common in communities served by multiple affiliate hospitals in the healthcare system and align with system priority areas, warranting a system level strategy. The Community Health Division and Office of Health Equity Research and Engagement (HERE) plans and provides technical assistance for strategies that

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 3. Community Benefit (continued)

address these common needs including health equity, tobacco, behavioral health access, infant and maternal health, hypertension, and social determinants of health. Each affiliate hospital works collaboratively with the Community Health Division and HERE to align and activate local resources to support these strategies. This benefits the community each affiliate hospital serves and works towards a statewide impact on health outcomes. The costs of providing these programs and services are included in total operating expenses on the accompanying consolidated statements of operations and changes in net assets.

### 4. Summary of Significant Accounting Policies

### **Principles of Consolidation**

The accompanying consolidated financial statements include the accounts of Indiana University Health and all majority-owned or controlled subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

#### **Use of Estimates**

The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

#### **Cash Equivalents**

Cash equivalents include highly liquid short-term investments with maturities of 90 days or less from the date of purchase, other than those included in assets limited as to use.

The Indiana University Health System routinely invests in money market funds, including treasury and agency money market funds, that are considered by management to be cash equivalents. Such instruments, as well as bank deposits, are potentially subject to concentrations of credit risk. In order to mitigate such risk, the Indiana University Health System generally places its cash and cash equivalents with institutions of high credit quality.

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

### 4. Summary of Significant Accounting Policies (continued)

#### **Patient Accounts Receivable**

Patient accounts receivable are based upon the estimated amounts expected to be paid from patients and third-party payers.

#### **Inventories**

Inventories consist primarily of drugs and supplies, are stated at the lower of cost or net realizable value, and are generally valued using the average cost method.

#### Assets Limited as to Use

Assets limited as to use include the following: (i) cash and cash equivalents and designated investment assets, including those funds held by the consolidated foundations, set aside by the Board for future capital improvements, over which the Board retains control and may, in certain circumstances, use for other purposes; (ii) current portion of assets limited as to use includes funds held by a trustee; and (iii) donor-restricted investment assets, the use of which has been specified by the donor. Substantially all assets limited as to use are invested and managed by professional investment managers and are held in custody by financial institutions. These funds are classified as trading securities. Accordingly, changes in unrealized gains and losses in the fair value of investments are included in nonoperating (loss) income within investment (loss) income on the accompanying consolidated statements of operations and changes in net assets. The Indiana University Health System is a limited partner in certain funds that employ hedged investment strategies and funds that employ investment strategies that require long holding periods to create value (collectively referred to as alternative investments). These alternative investments are accounted for using the equity method of accounting, based on the fund's financial information. Management has utilized the best available information for reported alternative investment values, which in some instances are valuations as of an interim date (see Note 6).

Funds totaling an initial \$700,000 for community health have been set aside and allocated to three separate funds: (i) a contribution of \$200,000 to the community impact investment fund to help address critical health issues affecting Hoosiers over the long term; (ii) \$200,000 to the health district investment fund was to support needs related to the health district, the area that will be developed in conjunction with the new Adult Academic Health Center; and (iii) \$300,000 to the health district support fund for additional needs, including onetime

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 4. Summary of Significant Accounting Policies (continued)

support for projects such as urban agriculture and revitalizing areas in the health district. These three funds are recorded as Board-designated funds – community health on the consolidated balance sheets as of December 31, 2022 and 2021.

Additionally, funds totaling \$400,000 were earmarked to establish the innovation investment fund for use in future health care innovation initiatives. These funds are recorded as Board-designated funds – innovation on the consolidated balance sheets as of December 31, 2022 and 2021.

The Indiana University Health, Inc. Board retains control of the community health and innovation Investment funds. The community health and innovation investment funds are subject to market fluctuations similar to other assets limited as to use.

## **Property and Equipment**

Property and equipment are stated at cost and are depreciated using the straight-line method over the estimated useful lives of the assets.

Interest cost incurred on borrowed funds during the period of construction and other interest costs related to tax-exempt bonds are capitalized as a component of the cost of constructing the assets. In addition, interest earnings on unexpended borrowed funds related to tax-exempt financings offset capitalized tax-exempt interest. Repair and maintenance costs are expensed when incurred.

The Indiana University Health System evaluates when events or changes in circumstances have occurred which would indicate that the remaining estimated useful life of long-lived assets warrants revision or that the remaining balance of such assets may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset or asset group. If undiscounted cash flows are insufficient to recover the carrying value of the long-lived asset, such asset is written down to its fair value (see Note 8).

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 4. Summary of Significant Accounting Policies (continued)

#### Interest in Unconsolidated Subsidiaries

The Indiana University Health System has joint venture arrangements for healthcare-related services in which it owns 50% or less. Where applicable, these arrangements are accounted for using the equity method of accounting. Total interest in unconsolidated subsidiaries was \$17,028 and \$15,380 as of December 31, 2022 and 2021, respectively. The Indiana University Health System has recorded its interest in the income of its unconsolidated subsidiaries within other operating revenue on the consolidated statements of operations and changes in net assets.

#### Leases

Indiana University Health leases property and equipment under finance and operating leases. Indiana University Health determines whether an arrangement is a lease at inception. For leases with terms greater than 12 months, Indiana University Health records the related right-of-use assets and lease liabilities at the present value of lease payments over the term. Leases may include rental escalation clauses and options to extend or terminate the lease that are factored into the determination of lease payments when appropriate. Indiana University Health does not separate lease and non-lease components of contracts. For the purposes of measuring the lease liabilities, Indiana University Health uses a risk-free rate from the U.S. Treasury constant maturities nominal rate based on the period comparable with that of each lease term.

Operating leases are included in right-of-use assets, current portion of lease liabilities, and lease liabilities, less current portion on the consolidated balance sheets. Operating lease expense is recognized on a straight-line basis over the lease term and is included in supplies, drugs, purchased services, and other on the consolidated statements of operations and changes in net assets.

Finance leases are included in property and equipment, current portion of long-term debt, and long-term debt, less current portion on the consolidated balance sheets. Property and equipment under finance lease obligations are amortized on the straight-line method over the lease term or the estimated useful life of the equipment, whichever period is shorter. Such amortization is included with depreciation on the accompanying consolidated statements of operations and changes in net assets (see Note 13).

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 4. Summary of Significant Accounting Policies (continued)

#### Goodwill and Intangible Assets

In connection with business combinations, the Indiana University Health System has recorded goodwill and definite-lived intangible assets on the accompanying consolidated balance sheets. The Indiana University Health System evaluates goodwill for impairment annually or more frequently if events or changes in circumstances suggest that the carrying value of an asset may not be recoverable. The goodwill impairment analysis, performed at the reporting unit level, generally includes estimating the fair value of a reporting unit and comparing that with the carrying value. If fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is not considered to be impaired. These valuation methods require the Indiana University Health System to make estimates and assumptions regarding future operating results, cash flows, changes in working capital, capital expenditures, profitability, and the cost of capital.

The Indiana University Health System also reviews whether events or changes in circumstances suggest that impairment may have occurred related to the carrying value of the definite-lived intangible assets, which are amortized over periods of 5 to 35 years. It has been determined that there was no impairment of goodwill or definite-lived intangible assets during 2022 or 2021. Intangible assets included in goodwill, intangibles, and other assets on the accompanying consolidated balance sheets as of December 31, 2022 and 2021, were \$206,728 and \$208,167, respectively, which includes goodwill of \$197,989 at December 31, 2022 and 2021.

#### Unamortized Bond Issuance Costs and Bond Discount or Premium

Costs incurred in connection with the issuance of long-term debt and bond discounts or premiums are amortized or accreted using the effective interest rate method. Amortization and accretion are included in interest expense on the accompanying consolidated statements of operations and changes in net assets (see Note 9).

#### **Derivative Financial Instruments**

The Indiana University Health System has entered into certain interest rate swap transactions (fixed-pay swaps and basis swaps). As of December 31, 2022 and 2021, the Indiana University Health System's fixed-pay swaps qualified for hedge accounting, whereas the basis

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 4. Summary of Significant Accounting Policies (continued)

swap as of those dates did not qualify for hedge accounting. Changes in fair value of interest rate swaps not designated as hedges, as well as the ineffective portion of the change in fair value of any interest rate swaps designated as hedges, during these years are reported in nonoperating (loss) income on the consolidated statements of operations and changes in net assets. Changes in fair value of interest rate swaps designated as hedges are included in other changes in net assets without donor restrictions on the consolidated statements of operations and changes in net assets (see Note 10).

#### Contributions

Unconditional promises to give cash and other assets are reported at fair value at the date the promise is made. Conditional promises to give, including indications of an intention to give, are not recognized until the condition is satisfied. If the gifts are made with donor stipulations that limit the use of the donated assets, the gifts are reported as donor restricted. Donor-restricted contributions for which restrictions are met in the same year as made are reported as unrestricted contributions in the accompanying consolidated financial statements.

#### **Net Assets With Donor Restriction**

Donor-restricted net assets are those assets whose use has been limited by donors to a specific time period or purpose. These net assets are generally restricted for medical education and research programs, medical supplies and equipment, and patient care services. Interests in net assets of unconsolidated foundations are included in other assets on the accompanying consolidated balance sheets (see Note 17).

#### Noncontrolling Interest in Subsidiaries

The Indiana University Health System recorded \$127,859 and \$151,792 for the years ended December 31, 2022 and 2021, respectively, of excess of revenues over expenses attributable to noncontrolling interest in subsidiaries based on the ownership percentage of the noncontrolling interests in certain of the Indiana University Health System's consolidated subsidiaries. These amounts primarily relate to the surgery center joint ventures. For the years ended December 31, 2022 and 2021, the surgery center joint ventures accounted for \$127.820 and \$148,996, respectively, of the excess of revenues over expenses attributable

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

### 4. Summary of Significant Accounting Policies (continued)

to noncontrolling interest in subsidiaries. The surgery center joint ventures realized operating revenue of \$357,006 and \$374,292 and operating income of \$157,288 and \$200,531 in 2022 and 2021, respectively. The operating revenue and operating income are reflected in total operating revenue and total operating income, respectively, on the consolidated statements of operations and changes in net assets.

#### **Business Combinations**

The Indiana University Health System allocates the purchase price of an acquisition to the various assets and liabilities based upon the relative fair value, which may be derived from various observable or unobservable inputs and assumptions. Also, the Indiana University Health System may use third-party valuation specialists. These components typically include buildings, land, and equipment and may also include intangibles related to noncompete agreements or other specifically identified intangible assets. The excess of the fair value of assets acquired over liabilities assumed and the fair value of any noncontrolling interest are recorded as an inherent contribution within the performance indicator as defined below. Goodwill is recorded to the extent that liabilities assumed and noncontrolling interests exceed the fair value of assets acquired.

#### **Fair Values of Financial Instruments**

Financial instruments include cash and cash equivalents, patient and other accounts receivable, assets limited as to use, accounts payable and accrued expenses, estimated third-party payer allowances, notes payable to banks, long-term debt, derivative financial instruments (i.e., fixed-pay and basis swaps), and certain other current assets and liabilities. The fair values for cash and cash equivalents, patient and other accounts receivable, accounts payable and accrued expenses, estimated third-party payer allowances, and certain other current assets and liabilities approximate the carrying amounts reported on the consolidated balance sheets and, in the opinion of management, represent highly liquid assets or short-term obligations. The fair values for assets limited as to use, and derivative financial instruments are described in Notes 6, 10, and 11.

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 4. Summary of Significant Accounting Policies (continued)

#### Member Premium Revenue and Health Claims

The Indiana University Health System has agreements to provide medical services to subscribing participants or members that generally provide for predefined payments (on a per member, per month basis), regardless of services actually performed. The cost to provide health care services under these agreements is accrued in the period in which the health care services are provided to a member based, in part, on estimates, including an accrual for medical services provided but not yet reported. Expenses to providers are reported as health claims to providers on the accompanying consolidated statements of operations and changes in net assets. The accrual for medical services provided but not yet reported is reflected as accrued health claims on the accompanying consolidated balance sheets.

#### **Income Taxes**

The Internal Revenue Service has determined that Indiana University Health and certain of its affiliated entities are tax-exempt organizations as defined in Section 501(c)(3) of the Internal Revenue Code (IRC). Indiana University Health and its tax-exempt affiliates are, however, subject to federal and state income taxes on unrelated business income under the provisions of IRC Section 511.

Deferred income taxes that, as of December 31, 2022 and 2021, have no net carrying value reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes. As of December 31, 2022 and 2021, the Indiana University Health System had gross deferred tax assets of \$145,194 and \$146,281, respectively, primarily relating to net operating loss carryovers. Management determined that a full valuation allowance at December 31, 2022 and 2021, was necessary to reduce the deferred tax assets to the amount that would more likely than not be realized. Based on the weight of the evidence, if it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance to reduce the deferred tax assets is recorded. At December 31, 2022, Indiana University Health System has available net operating loss carryforwards of \$583,788. Net operating losses generated from 2001 through 2017 will expire between 2022 and 2037. Net operating losses generated after 2017 do not expire.

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 4. Summary of Significant Accounting Policies (continued)

#### **Operating and Performance Indicators**

The primary purpose of Indiana University Health is to provide quality health care services to meet the needs of the State of Indiana. Since substantially all resources are derived from providing health care services, the activities directly associated with the furtherance of this purpose are considered operating activities. These activities serve as an important factor in evaluating how well management has discharged its stewardship responsibilities:

Operating Indicator (Operating Income) – Includes all unrestricted revenue, gains, donor contributions to offset operating expenses, other support, equity income or loss of unconsolidated health care subsidiaries, and expenses directly related to the recurring and ongoing health care operations during the reporting period. Any activities peripheral to Indiana University Health's primary purpose are excluded from the operating indicator and are considered nonoperating.

Performance Indicator [(Deficit) Excess of Revenues Over Expenses)] – Includes operating income and nonoperating income. The performance indicator excludes certain changes in the fair value of interest rate swaps designated as hedges; purchases of noncontrolling interests; and contributions for capital expenditures, distributions to noncontrolling interest, and net assets released from restricted funds.

#### **Subsequent Events**

For the consolidated financial statements as of and for the year ended December 31, 2022, management has evaluated subsequent events through February 23, 2023, the date that these consolidated financial statements were made publicly available.

### 5. Patient Service and Other Operating Revenue

The Indiana University Health System provides health care services through inpatient, outpatient, and ambulatory care facilities. The Indiana University Health System recognizes patient service revenue at the amount that reflects the consideration to which the Indiana University Health System expects to be paid for providing patient care. Patient service revenue is recognized as performance obligations, based on the nature of the services provided by the Indiana University Health System, are satisfied. Performance obligations satisfied over time

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 5. Patient Service and Other Operating Revenue (continued)

relate to patients in the Indiana University Health System hospitals who are receiving inpatient acute care services from admission to the point when services are no longer required, which is generally at the time of discharge.

Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected or actual charges. Outpatient services are performance obligations satisfied at a point in time, and revenue is recognized when goods or services are provided and the Indiana University Health System does not believe it is required to provide additional goods or services. Management believes this method provides a fair depiction of the transfer of services over the term of performance obligations, based on the inputs needed to satisfy the obligations.

Because all of its performance obligations relate to contracts with a duration of less than one year, the Indiana University Health System has elected to apply the optional exemption provided in Financial Accounting Standards Board Accounting Standards Codification 606-10-50-14(a) and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially satisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

The Indiana University Health System uses a portfolio approach to account for categories of patient contracts as a collective group, rather than recognizing revenue on an individual contract basis. The portfolios consist of major payer classes for inpatient revenue and outpatient revenue. Based on the historical collection trends and other analysis, the Indiana University Health System believes that revenue recognized by utilizing the portfolio approach approximates the revenue that would have been recognized if an individual contract approach were used.

The Indiana University Health System determines the transaction price, which involves significant estimates and judgment, based on standard charges for goods and services provided, reduced by explicit and implicit price concessions, including contractual adjustments provided to third-party payers, discounts provided to uninsured and

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 5. Patient Service and Other Operating Revenue (continued)

underinsured patients in accordance with policy, and/or implicit price concessions based on the historical collection experience of patient accounts. The Indiana University Health System determines the transaction price associated with services provided to patients who have third-party payer coverage with Medicare, Medicaid, managed care programs, and other third-party payers based on reimbursement terms per contractual agreements, discount policies, and historical experience. Payment arrangements with those payers include prospectively determined rates per admission or visit, reimbursed costs, discounted charges, per diem rates, and value-based payments. Reported costs and/or services provided under certain arrangements are subject to retroactive audit and adjustment. Changes in estimates due to settlements of prior fiscal years' cost reports, Medicaid settlements, and the disposition of other payer audits and settlements were not significant. Future changes in Medicare and Medicaid programs and reduction in funding levels could have an adverse effect on the Indiana University Health System. There were no other significant changes to the judgments used to determine the transaction price in prior periods.

The Indiana University Health System serves Medicaid patients and is subject to reimbursement under various programs. Under the Medicaid Hospital Assessment Fee program, the Office of Medicaid Policy and Planning collects a fee from eligible hospitals. The fee is used in part to increase reimbursement to eligible hospitals for services provided in both Medicaid fee-for-service and managed care programs, and as the State's share of disproportionate hospital share (DSH) payments. The State DSH program is dependent on regulatory approval by agencies of the federal and state governments and is determined by the level, extent, and cost of uncompensated care (as defined) and various other factors. Separately, the upper payment limit reimbursement program, now known as the Physician Faculty Access to Care program, was established to pay qualifying providers the difference between what Medicare would have paid and what Medicaid actually paid.

For the years ended December 31, 2022 and 2021, payments recognized related to these programs were recorded within patient service revenue on the consolidated statements of operations and changes in net assets, totaling \$729,477 and \$641,039, respectively. During the years ended December 31, 2022 and 2021, assessment fees were recorded within the hospital assessment fee line on the consolidated statements of operations and changes in net assets, totaling \$206,632 and \$185,979, respectively.

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 5. Patient Service and Other Operating Revenue (continued)

These revenues are subject to retroactive adjustments due to audits, reviews, changes in program administration and rules, and outcome of litigation. These settlements are estimated based on the agreement with the payer and correspondence, which includes an assessment to ensure it is probable that a significant reversal in the amount of cumulative revenue recognition will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known or as years are settled or are no longer subject to audits or reviews.

Laws and regulations governing Medicare, Medicaid, and other governmental programs are complex, prone to changes, and subject to varying interpretation. The Indiana University Health System believes it is in compliance with applicable laws and regulations governing Medicare, Medicaid, and other governmental programs, as well as contracts that it has with commercial payers, and that adequate provisions have been recorded for any adjustments that may result from final settlements.

In support of its mission, the Indiana University Health System provides care to uninsured and underinsured patients. The Indiana University Health System provides charity care to patients who lack the financial resources to pay for their medical care. Financial assistance is available to qualifying uninsured and underinsured patients receiving care at an Indiana University Health System hospital location. Under its financial assistance policy, the Indiana University Health System provides medically necessary care to uninsured patients. Financial assistance up to the full amount of patient financial responsibility is available for uninsured and underinsured patients receiving care via the emergency department, direct admission from a physician's office, or transfer from another hospital. The federal poverty level (FPL) thresholds are used when determining the level of financial assistance based on household makeup. Households without dependents are eligible for assistance if household income is less than or equal to 200% FPL, two adults and at least one dependent are eligible if household income is less than or equal to 250% FPL, and households with one adult and at least one dependent are eligible if household income is less than or equal to 300% FPL. Individuals with medical bills totaling more than 20% of annual household income, regardless of FPL, qualify for catastrophic assistance and are eligible for a reduction in patient financial responsibility to 20% of annual household income. Since the Indiana University Health System does not pursue collection of these amounts, the discounted amounts are not reported as patient service revenue. The Indiana University Health System uses presumptive eligibility screening procedures for some forms of financial assistance and recognizes net patient service revenue

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 5. Patient Service and Other Operating Revenue (continued)

on services provided to self-pay patients at the discounted rate at the time services are rendered. The estimated cost of charity care, using the consolidated cost to charge ratio, was \$88,213 and \$133,584 in 2022 and 2021, respectively.

In rare instances, the Indiana University Health System receives payment in advance of the services provided and considers these amounts to represent contract liabilities. No contract liabilities were recorded as of December 31, 2022. Contract liabilities as of December 31, 2021, were \$205,162 and were a result of funds received as part of the Medicare Accelerated and Advance Payment Program (see Note 2). For the years ended December 31, 2022 and 2021, \$205,162 and \$143,286, respectively, of the funds were recouped and offset accounts receivable on the consolidated balance sheets.

Management has determined that the nature, amount, timing, and uncertainty of revenue and cash flows are affected by the payers and lines of business that render services to patients. The composition of patient service revenue by payer was as follows:

	Year Ended	Year Ended December 31			
	2022	2021			
Commercial/managed care	\$3,978,943	\$3,870,640			
Medicare	1,963,992	1,834,750			
Medicaid	1,493,390	1,392,028			
Self-pay and other	102,529	111,236			
	\$7,538,854	\$7,208,654			

The Indiana University Health System's practice is to assign a patient to the primary payer and not reflect other uninsured balances (for example, co-pays and deductibles) as self-pay. Therefore, the payers listed above contain patient responsibility components, such as co-pays and deductibles.

One payer represented 30% and 31% of patient service revenue for December 31, 2022 and 2021, respectively.

The Indiana University Health System does not require collateral or other security from its patients, substantially all of whom are residents of the State, for the delivery of health care

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 5. Patient Service and Other Operating Revenue (continued)

services. However, consistent with industry practice, the Indiana University Health System routinely obtains assignment of (or is otherwise entitled to receive) patients' benefits payable under their health insurance programs, plans, or policies (e.g., Medicare, Medicaid, managed care payers, and commercial insurance policies). As of December 31, 2022 and 2021, 29% of patient accounts receivable were collectible from government payers. The remaining 71% of patient accounts receivable in 2022 and 2021 were collectible from managed care payers, commercial insurance payers, and uninsured and underinsured patients.

Other revenue is recognized at an amount that reflects the consideration to which the Indiana University Health System expects to be entitled in exchange for providing goods and services.

The amounts recognized reflect consideration due from customers, third-party payers, and others. Primary categories of other revenue include income from joint ventures, grant revenue, cafeteria revenue, and rent and lease revenue.

The composition of other revenue by sources is as follows:

	Year Ended December 31 2022 2021			
Shared health services revenue Stimulus funds and tax credits Other	\$	166,860 17,183 73,734	\$	170,178 107,924 101,081
	\$	257,777	\$	379,183

#### 6. Assets Limited as to Use

Board-designated and donor-restricted investment funds are invested in accordance with Board-approved policies. The estimated fair value of the assets limited as to use is determined using market information and other appropriate valuation methodologies. The methods and assumptions used to estimate the fair value of assets limited as to use are as follows: (i) cash and cash equivalents: the carrying amounts reported on the consolidated balance sheets approximate fair value; (ii) marketable securities: the fair values are based on quoted market prices or, if quoted market prices are not available, quoted market prices of comparable instruments and other observable inputs; and (iii) other investments, including alternative

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 6. Assets Limited as to Use (continued)

investments: accounted for using the equity method of accounting, and fair values are based upon the net asset values that are generally determined by third-party valuation firms and/or administrators of each fund in consultation with and approval of the fund investment managers.

The Indiana University Health System is a limited partner in funds that employ hedged investment strategies and private funds that employ investment strategies that require long holding periods to create value, both of which are mainly utilized to increase portfolio diversification.

In the case of hedge funds, redemptions generally may be made quarterly with written notice ranging from 30 to 90 days; however, some funds employ lockup periods that restrict redemptions or charge a redemption fee during the lockup period. Lockup periods range from one to three years, with redemption charges of up to 5% of net asset value for redemptions made on or before the anniversary date of the initial investment or additional contribution. Upon complete redemption, many of the funds have "hold-back" provisions that allow the fund to retain up to 10% of the assets until the fund completes its audited financial statements for the redemption period.

In the case of private funds, capital is returned as monetization events occur. These events are typically infrequent in nature. Generally, capital is committed to a partnership for a period of five to ten years with the ability of the general partner to extend the life of the fund one to three additional years. During the first three to five years of a fund life, the general partner, in order to facilitate its funding of investments, will call capital from the limited partners up to the amount of their commitment. As of December 31, 2022 and 2021, there were \$959,704 and \$693,545, respectively, of unfunded commitments relating to private fund investments, which are expected to be funded over the next five years.

Alternative investments include certain other risks that may not exist with other investments that are more widely traded. These include reliance on the skill of the fund managers, who often employ complex strategies utilizing various financial instruments, including futures contracts, foreign currency contracts, structured notes, interest rate, total return, and credit default swaps.

Additionally, alternative investments may provide limited information on a fund's underlying assets and have restrictive liquidity provisions. Management believes that the Indiana

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 6. Assets Limited as to Use (continued)

University Health System, in consultation with its investment consultants, has the capacity to analyze and interpret the risks associated with alternative investments and, with this understanding, has determined that these investments represent a prudent approach for use in its portfolio management.

Indiana University Health's asset allocation policy is to target a modest amount of leverage to achieve a total exposure of 110%. The utilization of this increased exposure within the policy aims to enhance both returns and risk characteristics (i.e., diversification) of the Board-designated investment funds in assets limited as to use.

Indiana University Health primarily utilizes futures contracts to provide exposure to markets such as equity and fixed income. The notional value of futures contracts was approximately \$620,662 and \$851,038 as of December 31, 2022 and 2021, respectively. The fair values of futures contracts included in assets limited as to use on the consolidated balance sheet were \$2,760 and \$1,320 as of December 31, 2022 and 2021, respectively. (Losses) gains attributed to these futures contracts were \$(104,288) and \$57,462 for the years ended December 31, 2022 and 2021, respectively, and are included in investment (loss) income, net on the consolidated statements of operations and changes in net assets.

Indiana University Health also utilizes total return swaps to provide exposure to fixed-income markets. The notional value of total return swaps was \$69,693 as of December 31, 2022. The fair value of total return swap contracts and associated collateral posted was (\$563) and \$420, respectively, as of December 31, 2022. Indiana University Health has elected to offset these values and record the net fair value in assets limited as to use on the consolidated balance sheet. The loss attributed to the total return swaps was \$563 for the year ended December 31, 2022, and is included in investment (loss) income, net on the consolidated statement of operations and changes in net assets. The notional value of total return swaps was \$49,492 as of December 31, 2021. The fair value of total return swap contracts and associated collateral posted was (\$54) and \$150, respectively, as of December 31, 2021.

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

## 6. Assets Limited as to Use (continued)

The composition of assets limited as to use is set forth below.

	December 31			
		2022		2021
Assets limited as to use:				
Cash	\$	98,461	\$	163,732
Short-term, liquid investments		36,184		-
Debt securities:				
Asset backed		152,459		218,246
Bank loans		256,566		344,076
Corporate debt		546,547		849,941
Government and agencies		388,005		603,258
Bond funds		154,138		203,031
Total debt securities	1	L,497,715		2,218,552
Equity securities:				
Domestic equities	1	1,638,851		2,294,618
Domestic equity funds		15,261		23,011
International equities		707,759		933,667
International equity funds		288,664		404,733
Total equity securities	- 2	2,650,535		3,656,029
Alternatives:				
Hedge funds	-	1,211,145		1,208,133
Private funds		L,429,259		1,039,898
Other	_	2,616		1,418
Total alternatives		2,643,020		2,249,449
Less current portion of assets limited as to use	-	(171,132)		(176,167)
Total assets limited as to use	\$ 6	6,754,783	\$	8,111,595
. 513 355515	<u> </u>	-,,	Ψ	-,,

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 6. Assets Limited as to Use (continued)

Assets limited as to use include funds held by the foundations whose fair values as of December 31, 2022, aggregated to \$264,323, of which \$167,412 is considered Board-designated investment funds and \$96,911 is considered donor-restricted investment funds. As of December 31, 2021, the fair values aggregated to \$277,130, of which \$177,285 is considered Board-designated investment funds and \$99,845 is considered donor-restricted investment funds.

The composition and presentation of investment (loss) income, net, recognized in nonoperating (loss) income on the accompanying consolidated statements of operations and changes in net assets are as follows:

	Year Ended December 31			
		2022		2021
Investment (loss) income:				
Interest and dividend income	\$	175,733	\$	174,255
Investment management and administrative fees		(12,345)		(11,713)
Realized (losses) gains on sale of investments, net		(129,114)		290,012
Change in unrealized (losses) gains on investments		(887,660)		341,599
Unrealized equity gains on alternative investments		155,226		88,692
	\$	(698,160)	\$	882,845

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 7. Financial Assets and Liquidity Reserves

The table below represents financial assets and liquidity resources available for general expenditures within one year as of December 31, 2022 and 2021. The Indiana University Health System defines general expenditures as the normal expenditures related to operations of the Indiana University Health System, excluding capital expenditures.

	December 31			
	2022 2021			
Financial assets:				
Cash and cash equivalents	<b>\$ 342,828</b> \$ 263,492			
Short-term investments	<b>22,916</b> 9,136			
Patient accounts receivable	<b>1,008,169</b> 1,058,084			
Other receivables	<b>90,448</b> 85,945			
Assets limited as to use	<b>6,925,915</b> 8,287,762			
Total financial assets	<b>8,390,276</b> 9,704,419			
Liquidity resource: Unused bank lines of credit	<b>280,000</b> 225,000			
Less amounts not available within one year or not designated for general expenditures:				
Alternative investments	<b>(1,561,114)</b> (1,199,245)			
Other	<b>(244,303)</b> (272,767)			
Financial assets not available for use within one year	<b>(1,805,417)</b> (1,472,012)			
Financial assets and liquidity resources available for general expenditures within one year	<b>\$6,864,859</b> \$8,457,407			

The Indiana University Health System has certain Board-designated assets limited as to use that are available for general expenditures within one year in the normal course of operations. The Indiana University Health System maintains a liquidity pool with a target range of \$150,000 to \$550,000, which comprises cash equivalents and debt securities with maturities ranging from zero to three years and is reflected in cash and cash equivalents, short-term investments, and assets limited as to use on the consolidated balance sheets. Alternative investments not available within one year consist of the private funds, as well as a portion of the hedge funds due to contractual restrictions that prevent redemption of all or portions of such funds within a year.

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 7. Financial Assets and Liquidity Reserves (continued)

Additionally, the "Other" amounts not available within one year include Board-designated investments within the general liability captive insurance program, foundation assets not available within one year or for general expenditures, and other restricted cash.

## 8. Property and Equipment

The cost of property and equipment is summarized as follows:

	Decen	December 31			
	2022	2021			
Land and improvements Buildings and improvements Equipment	\$ 420,608 4,080,324 2,616,945	\$ 342,583 3,836,779 2,641,336			
	<u>\$7,117,877</u>	\$6,820,698			

Useful lives of each category of assets are based on the estimated useful time frame that the particular assets are expected to be in service, generally in accordance with guidelines established by the American Hospital Association. Assets are depreciated on a straight-line basis beginning in the month when placed in service, with asset lives ranging as follows: 20 to 30 years for land improvements; 15 to 40 years for buildings and improvements; and 3 to 10 years for equipment, including software developed for internal use.

The Indiana University Health System has several approved large capital projects within construction-in-progress. As of December 31, 2022, the projects primarily include the consolidation of the downtown Indianapolis adult services into one medical campus, while December 31, 2021, primarily comprises renovations to Riley Hospital in order to integrate maternity and neonatal services, construction of a regional health campus and replacement hospital in Bloomington, and an expansion and renovation of West.

Construction-in-progress for assets currently under development was \$366,757 and \$131,237 at December 31, 2022 and 2021, respectively, and includes incurred costs for these projects and the construction, refurbishment, and replacement of other facilities and equipment. Firm commitments for future construction-in-progress spending totaled \$527,646 at December 31, 2022.

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 9. Debt

#### **Obligated Group**

The Indiana University Health System operates under a single Master Trust Indenture (MTI). The MTI provides for the issuance of long-term debt and sets forth the terms pursuant to which underlying debt is issued and the security for such obligations. The MTI also sets forth the provisions governing membership for the Obligated Group, which presently consists of Indiana University Health (entity that includes such divisions as the Downtown Indianapolis Hospitals of the Academic Health Center, Saxony, and Morgan) as the sole member. Future members of the Obligated Group, if any, together with existing members will be jointly and severally liable for the obligations under the MTI. Under the terms of the MTI, the Obligated Group is required to comply with certain covenants, including financial performance covenants that, among other compliance requirements, require the maintenance of debt service coverage ratios and limit its ability to encumber certain of its assets. All Obligations Outstanding under the MTI are secured by security interests in the Gross Receivables of the Obligated Group Members (capitalized terms in this sentence not otherwise defined herein have the meanings assigned to them in the MTI). As of December 31, 2022, the Indiana University Health System was in compliance with all financial covenants.

#### Issuance, Modification, and Extinguishment of Debt

On June 16, 2022, Indiana University Health terminated its existing line of credit and entered into a new syndicated line of credit. The outstanding balance on the existing line of credit was transferred to the new syndicated line of credit. This new syndicated line of credit comprised of three tranches totaling \$500,000. Tranche A is \$130,000 and has a maturity date of July 1, 2025. Tranche B is \$130,000 and has a maturity date of July 1, 2026. Tranche C is \$240,000 and has a maturity date of July 1, 2027. As of December 31, 2022, \$220,000 is outstanding on the line of credit. As of December 31, 2021, no amounts were drawn on the line of credit.

On July 1, 2021, Indiana University Health issued \$300,000 in par value of Series 2021A taxable, fixed-rate bonds. On the same day, Indiana University Health effectuated the conversion and public remarketing of the following bonds: (i) \$58,225 at par of Series 2011L bonds as tax-exempt, fixed-rate mandatory tender bonds and (ii) \$49,565 at par of Series 2011M bonds as tax-exempt, fixed-rate mandatory tender bonds. Proceeds of the Series 2021A bonds were used for general corporate purposes and to pay certain expenses incurred

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

## 9. Debt (continued)

in connection with their issuance and the conversion and remarketing of the Series 2011L and 2011M bonds.

Long-term debt consists of the following:

	December 31			
		2022		2021
Indiana University Health Obligated Group				
Fixed-Rate, Taxable Bonds, Series 2021A, payable in a single principal installment at maturity in 2051, with an interest rate of 2.85% at				
December 31, 2022 and 2021	\$	300,000	\$	300,000
Fixed-Rate, Taxable Bonds, Series 2018A, payable in a single principal installment at maturity in 2048, with an interest rate of 3.97% at				
December 31, 2022 and 2021		393,408		393,408
Indiana Finance Authority:		•		
Fixed-Rate, Tax-Exempt Health System Revenue Bonds, Series 2019A, payable in varying principal installments in 2047 and 2049, with an				
interest rate of 4.00% at December 31, 2022 and 2021		133,610		133,610
Fixed-Rate, Tax-Exempt Health System Revenue Bonds, Series 2019B, payable in varying principal installments in 2057 and 2058 and subject to mandatory tender and remarketing in 2025, with an				
interest rate of 2.25% at December 31, 2022 and 2021		109,070		109,070
Fixed-Rate, Tax-Exempt Health System Revenue Bonds, Series 2019C, payable in varying principal installments through 2024, with an		·		·
interest rate of 5.00% at December 31, 2022 and 2021		37,720		61,795
Fixed-Rate, Tax-Exempt Hospital Revenue Refunding Bonds, Series 2016A, payable in varying principal installments through 2025, with				
an interest rate of 5.00% at December 31, 2022 and 2021 Fixed-Rate, Tax-Exempt Hospital Revenue Refunding Bonds, Series		77,960		104,375
2015A, payable in varying principal installments through 2040, with interest rates ranging from 4.00% to 5.00% at December 31, 2022				
and 2021		287,395		287,395

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

## 9. Debt (continued)

		Deceml 2022	ber 3	31 2021
Fixed-Rate, Tax-Exempt Hospital Revenue Refunding Bonds, Series 2014A, payable in varying principal installments through 2030, with an interest rate of 5.00% at December 31, 2022 and 2021	\$	36,625	\$	40,805
Fixed-Rate, Tax-Exempt Hospital Revenue Bonds, Series 2011L and M, payable in varying principal installments through 2046 and subject to mandatory tender and remarketing in 2026, with an interest rate of 0.70% at December 31, 2022 and 2021		107,790		107,790
Variable Rate Commercial Bank Revolving Line of Credit, maturing in tranches from July 1, 2025 through July 1, 2027		220,000		-
Other debt				
Rehabilitation Hospital of Indiana Obligated Group Indiana Finance Authority: Fixed-Rate, Tax-Exempt Hospital Revenue Bonds, Series 2011A, with an interest rate of 2.22% at				
December 31, 2021, repaid in 2022		_		9,567
Finance lease obligations		2,009		1,298
Other		379		1,043
Total long-term debt		1,705,966		1,550,156
Unamortized premium, net of unamortized discount		44,193		51,983
Unamortized bond issuance costs		(9,480)		(9,948)
Less current portion	_	(54,027)		(56,718)
Long-term debt, less current portion	\$	1,686,652	\$	1,535,473

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

### 9. Debt (continued)

The scheduled maturities and mandatory redemptions of long-term debt, assuming remarketing of mandatory tender bonds, are as follows:

	Indiana University Health Obligated Group MTI Debt Other Total									
Year ending December 31:		Toup Will Debt		Outlet		Total				
2023	\$	52,885	\$	1,142	\$	54,027				
	Φ	,	Φ	,	Φ	•				
2024		50,735		747		51,482				
2025		155,890		289		156,179				
2026		95,075		90		95,165				
2027		5,330		77		5,407				
Thereafter	1	,343,663		43	1	L,343,706				
	\$1	,703,578	\$	2,388	\$1	L,705,966				

Total interest paid on long-term debt for the years ended December 31, 2022 and 2021, aggregated \$58,527 and \$56,394, respectively.

#### 10. Derivative Financial Instruments

During October 2021, Indiana University Health terminated fixed-pay interest rate swaps and recognized a loss of \$9,730 pursuant to the terminations. During November 2021, Indiana University Health terminated fixed-pay interest rate swaps and recognized a loss of \$23,014 pursuant to the terminations. The losses are recorded as (losses) gains on interest rate swaps on the consolidated statements of operations and changes in net assets.

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 10. Derivative Financial Instruments (continued)

Long-term interest rate swap arrangements have been entered into, with the primary objective of mitigating interest rate risk. The following fixed-pay swaps, stated at current and maximum future notional amounts, remain in place as of December 31, 2022:

 Current Notional Amount	Fut	Maximum ure Notional Amount	Rate Paid			
\$ -	\$	109,070 287,395	7/1/2025 6/1/2025	12/1/2058 12/1/2040	LIBOR LIBOR	0.93% 1.01

A In the tables above and below, LIBOR represents the one-month London Interbank Offered Rate and SIFMA represents the Securities Industry and Financial Markets Association Municipal Swap Index.

In addition, long-term basis swap arrangements were entered into for the purpose of managing the effect of interest rates on cash flows and were in place as of December 31, 2022, as follows:

C	urrent Notional Amount			Effective Date	Maturity Date	Swap Type	Rate Received <sup>A</sup>	Rate Paid <sup>A</sup>
\$	309,200	\$	309,200	1/7/2020	1/7/2033	Basis	75.00% LIBOR	SIFMA

Guidance on fair value accounting stipulates that a credit valuation adjustment (CVA) be applied to the mark-to-market valuation position of interest rate swaps to more closely capture the fair value of such instruments. Collateral arrangements reduce the credit exposure and are considered in determining the CVA.

As of December 31, 2022, the fair value of interest rate swaps in a liability position was \$10,360, which is net of CVA of \$1,221, and the fair value of interest rate swaps in asset positions was \$86,200, which is net of CVA of \$19,064. As of December 31, 2021, the fair value of interest rate swaps in a liability position was \$7,606, which is net of CVA of \$548, and the fair value of interest rate swaps in asset positions was \$32,839, which is net of CVA of \$5,917. The fair value of swaps in liability positions is included within noncurrent liabilities on the accompanying consolidated balance sheets. The fair value of swaps in asset positions is included within other assets on the accompanying consolidated balance sheets as of December 31, 2022 and 2021.

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 10. Derivative Financial Instruments (continued)

As of December 31, 2022, interest rate swaps had a total current notional amount of \$309,200, comprising \$309,200 of basis swaps, and maximum future notional amount of \$705,665, comprising \$396,465 of fixed-pay swaps and \$309,200 of basis swaps. Under agreements executed with counterparties, Indiana University Health is obligated to fund collateral amounts when the aggregate market value of swaps made with a given counterparty is a liability that exceeds a threshold set forth in the related agreement. The counterparty is also required to pledge collateral. As of December 31, 2022 and 2021, all interest rate swaps were subject to credit-risk-related contingent features. No collateral was posted as of December 31, 2022 or 2021.

The Indiana University Health System recorded the following (losses) gains within nonoperating (loss) income on the accompanying consolidated statements of operations and changes in net assets related to these derivative financial instruments:

(Losses) gains on interest rate swaps, net:
Unrealized (losses) gains on interest rate swaps
Change in realized due to swap terminations
Realized gains on interest rate swaps

Ye	Year Ended December 31										
	2022	2021									
<u> </u>											
\$	(2,747) \$	36,938									
	_	(32,744)									
	348	112									
\$	(2,399) \$	4,306									

The Indiana University Health System recorded the change in fair value of interest rate swaps designated as hedges of \$53,006 and \$18,207 as changes in net assets without donor restrictions on the consolidated statements of operations and changes in net assets for the years ended December 31, 2022 and 2021, respectively.

#### 11. Fair Value Measurements

The accounting guidance for the application of fair value provides, among other matters, for the following: (i) defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date and establishes a framework for measuring fair value, (ii) establishes a three-level hierarchy for fair value measurements based upon the observability of inputs to the valuation of an asset or a liability as of the measurement date, (iii) requires consideration

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

### 11. Fair Value Measurements (continued)

of nonperformance risk when valuing liabilities, and (iv) expands disclosures about instruments measured at fair value. The three-level hierarchy is based upon the nature of valuation techniques and whether such techniques are based upon observable or unobservable inputs, as defined.

Observable inputs are intended to reflect market data obtained from independent sources, while unobservable inputs may reflect market assumptions made by management or measurements made by financial specialists generally associated with the financial asset or liability. These two types of inputs create the following fair value hierarchy:

- Level 1 Quoted prices (unadjusted) in active markets for identical assets or liabilities as of the reporting date.
- Level 2 Pricing inputs other than quoted prices included in Level 1 that are either directly observable or that can be derived or supported from observable data as of the reporting date.
- Level 3 Pricing inputs include those that are significant to the fair value of the financial asset or financial liability and are not observable from objective sources. In evaluating the significance of inputs, the Indiana University Health System generally classifies assets or liabilities as Level 3 when their fair value is determined using unobservable inputs that, individually or when aggregated with other unobservable inputs, represent more than 10% of the fair value of the assets or liabilities. These inputs may be used with internally developed methodologies that result in management's best estimate of fair value.

Net Asset Value (NAV) – Indiana University Health invests in funds for which the NAV per share represents the fair value of the investment held. Some of the risks and redemption restrictions for these investments are similar to the alternative investments (see Note 6). Management opted to use the NAV per share, or its equivalent, as a practical expedient for the fair value of the interest in certain funds. Valuations provided by the respective fund's management consider variables such as the financial performance of underlying investments, recent sales prices of underlying investments, and other pertinent information.

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

### 11. Fair Value Measurements (continued)

The following tables set forth by level, within the fair value hierarchy, the Indiana University Health System's financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2022 and 2021. The financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment, could be subject to change or variation, and may affect the valuation of fair value assets and liabilities and their classification within the fair value hierarchy levels.

	December 31, 2022												
	Le	vel 1		Level 2		Level 3		NAV	Fa	ir Value	Equity Metho	d Ca	rrying Value
Assets													
Cash and cash equivalents	\$ 34	12,828	\$	-	\$	-	\$	-	\$ 3	342,828	\$ -	\$	342,828
Short-term investments:													
Debt securities:													
Asset backed		-		2,589		-		-		2,589	-		2,589
Corporate debt		-		20,327		-		_		20,327	-		20,327
Assets limited as to use:													
Cash and cash equivalents		8,461		-		-		_		98,461	-		98,461
Short-term, liquid investments	3	36,184		_		-		-		36,184	-		36,184
Debt securities:													
Asset backed		-		152,459		-		_		L52,459	-		152,459
Bank loans		-		253,484		3,082		-		256,566	-		256,566
Corporate debt		-		546,140		407		_		546,547	-		546,547
Government and agencies	38	35,651		2,354		-		<del>-</del>		388,005	-		388,005
Bond funds		-		-		-		154,138	1	L54,138	-		154,138
Equity securities:													
Domestic equities		36,108		-		2,743		-	1,6	38,851	-	-	1,638,851
Domestic equity funds		L5,261		-		_		_		15,261	-		15,261
International equities	70	7,759		-		_		<del>-</del>		707,759	-		707,759
International equity funds		-		-		-		288,664	2	288,664	-		288,664
Alternatives:													
Hedge funds		-		-		-		-		-	1,211,145		1,211,145
Private funds		<del>-</del>		-		_		_		<del>-</del>	1,429,259	-	1,429,259
Other		2,616		-		_		_		2,616	-		2,616
Other assets:													
Interest rate swaps		-		-		86,200		-		86,200	-		86,200
Beneficial interests in													
charitable remainder and													
perpetual trusts				17,247		_		_		17,247			17,247
Total assets	\$3,22	24,868	\$	994,600	\$	92,432	\$	442,802	\$4,7	754,702	\$2,640,404	\$	7,395,106
1.5.1.000													
Liabilities						40.000				40.000	•		40.000
Interest rate swaps	\$		<u> </u>		\$	10,360	\$	-	<u>\$</u>	10,360	<u>\$ -</u>	<u>\$</u>	10,360
Total liabilities	\$		\$	-	\$	10,360	\$	-	\$	10,360	\$ -	\$	10,360

## Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

### 11. Fair Value Measurements (continued)

		December 31, 2021										
	Level 1		Level 2		Level 3		NAV	Fair Value	Equity Method	l Carrying Value		
Assets												
Cash and cash equivalents	\$ 263,49	92	\$ -	\$	-	\$	_	\$ 263,492	\$ -	\$ 263,492		
Debt securities:												
Asset backed		-	62		-		_	62	_	62		
Corporate debt		-	9,074		-		_	9,074	_	9,074		
Assets limited as to use:												
Cash	163,73	32	_		_		_	163,732	-	163,732		
Debt securities:												
Asset backed		-	218,246		_		_	218,246	-	218,246		
Bank loans		-	344,076		_		_	344,076	-	344,076		
Corporate debt		-	847,376		2,565		_	849,941	-	849,941		
Government and agencies	597,33	33	5,925		-		_	603,258	_	603,258		
Bond funds		-	_		_		203,031	203,031	-	203,031		
Equity securities:												
Domestic equities	2,294,63	18	_		_		_	2,294,618	-	2,294,618		
Domestic equity funds	23,02	11	_		_		_	23,011	-	23,011		
International equities	933,66	37	_		_		_	933,667	_	933,667		
International equity funds		_	_		_		404,733	404,733	_	404,733		
Alternatives:												
Hedge funds		-	_		_		_	_	1,208,133	1,208,133		
Private funds		-	_		_		_	_	1,039,898	1,039,898		
Other	1,41	18	-		-		-	1,418	_	1,418		
Other assets:												
Interest rate swaps		-	-		32,839		-	32,839	_	32,839		
Beneficial interests in												
charitable remainder and												
perpetual trusts		-	20,345		-		_	20,345	_	20,345		
Total assets	\$4,277,2	71	\$1,445,104	\$	35,404	\$	607,764	\$6,365,543	\$2,248,031	\$8,613,574		
			·						<del></del>			
Liabilities												
Interest rate swaps	\$	-	\$ 7,606	\$		\$	_	\$ 7,606	\$ -	\$ 7,606		
Total liabilities measured at fair			<b>. . . . . . . . . .</b>					<b>.</b>		<b>4 7 200</b>		
value on a recurring basis	\$	_	\$ 7,606	\$		\$	_	\$ 7,606	\$ -	\$ 7,606		

Other investments in assets limited as to use include derivative contracts used in Indiana University Health's enhanced exposure strategy that do not qualify for hedge accounting and are recorded at fair value (see Note 6).

Beneficial interests in charitable remainder and perpetual trusts of \$17,247 and \$20,345 as of December 31, 2022 and 2021, respectively, are included in goodwill, intangibles, and other assets on the consolidated balance sheets.

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

### 11. Fair Value Measurements (continued)

The fair values of the interest rate swap contracts are determined based on the present value of expected future cash flows using discount rates appropriate with the risks involved. The valuations reflect a CVA (see Note 10) to the LIBOR discount curve in order to reflect the credit value adjustment for nonperformance risk. The Indiana University Health System credit spread adjustment for swaps in a liability position is derived from other comparably rated entities' bonds priced in the market. The credit spread adjustment for swaps in an asset position is derived from market values for bonds issued by institutions with comparable ratings to those of the relevant counterparty. Generally, swaps are transferred between Level 2 and Level 3 when the CVA exceeds 10% of the gross valuation of the swap. Transfers are recorded at the end of the reporting period. Due to the volatility of the capital markets, there is a reasonable possibility of changes in fair value and additional gains (losses) in the near term subsequent to December 31, 2022.

The following table is a rollforward of the amount included on the consolidated balance sheet for interest rate swaps classified within Level 3 of the valuation hierarchy defined above:

	December 31						
	 2022		2021				
Fair value at January 1	\$ 32,839	\$	_				
Transfers in	(7,612)		38,756				
Unrealized gains	63,088		_				
Other	(12,475)		(5,917)				
Fair value at December 31	\$ 75,840	\$	32,839				

There were no material transfers between Level 3 investments in 2022 and 2021.

The value of the CVA may vary depending upon the following factors:

 Whether the Indiana University Health System is required to post collateral under the swap agreements.

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

### 11. Fair Value Measurements (continued)

- To the extent that the credit rating of the Indiana University Health System or relevant counterparty increases or decreases, in which case the CVA would decrease or increase, respectively.
- To the extent that the spread between the interest rate curves discussed above expands or compresses.

### 12. Commitments and Contingencies

The Indiana University Health System is, from time to time, subject to various legal proceedings and claims arising in the ordinary course of business. The Indiana University Health System's management does not expect the outcome in any of its currently ongoing legal proceedings or the outcome of any other claims, individually or collectively, to have a material adverse effect on the Indiana University Health System's consolidated financial condition, results of operations, or cash flows.

#### 13. Leases

Indiana University Health has operating and finance leases for medical offices, administrative offices, and certain equipment. The leases have remaining lease terms of 1 year to 15 years, some of which may include options to extend.

Rent and lease expense, included in supplies, drugs, purchased services, and other expenses on the accompanying consolidated statements of operations and changes in net assets, amounted to \$60,471 and \$61,759 for the years ended December 31, 2022 and 2021, respectively.

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

## 13. Leases (continued)

Other information related to leases was as follows:

	Year Ended December 31				
		2022		2021	
Supplemental cash flow information					
Cash paid for amounts included in the measurement of lease liabilities:					
Operating cash flows from operating leases	\$	43,580	\$	43,082	
Operating cash flows from finance leases		13		32	
Financing cash flows from finance leases		701		469	
Right-of-use assets obtained in exchange for lease obligations:					
Operating leases	\$	64,184	\$	74,661	
Finance leases		1,395		1,294	
Weighted average remaining lease term (in years)		6.24		5.68	
Operating leases Finance leases		3.04		5.66 4.62	
Findrice reases		3.04		4.02	
Weighted average discount rate					
Operating leases		2.61%	'n	1.94%	
Finance leases		0.85	-	0.84	

Future net present value minimum lease payments under noncancelable leases as of December 31, 2022, were as follows:

	Operating			Finance	
0000		44.450			
2023	\$	41,152	\$	775	
2024		34,431		755	
2025		30,282		291	
2026		26,738		91	
2027		21,399		78	
Thereafter		36,999		44	
Total future minimum lease payments		191,001		2,034	
Less imputed interest		17,216		25	
Net present value of minimum lease payments	\$	173,785	\$	2,009	

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

#### 13. Leases (continued)

As of December 31, 2022, Indiana University Health reviewed leases that had been signed in 2022 with commencement dates in subsequent years. None of these agreements were deemed material for disclosure.

### 14. Medical Malpractice

The Indiana University Health System's medical malpractice coverage is provided through the IU Health Risk Retention Group, Inc. (IUHRRG), a 99%-owned subsidiary. The program of medical malpractice coverage considers the per claim limitation of liability prescribed by the Indiana Medical Malpractice Act (the Act), which limits the amount of individual claims to the following: (i) for acts of negligence prior to June 30, 2017, \$1,250 and annual aggregate claims to \$7,500, of which up to \$1,000 would be paid by the State of Indiana Patient Compensation Fund (the Fund) and \$250 by the Indiana University Health System for each occurrence of malpractice; (ii) for acts of negligence from July 1, 2017 to June 30, 2019, \$1,650 and annual aggregate claims to \$12,000 of which up to \$1,250 would be paid by the Fund and \$400 by the Indiana University Health System for each occurrence of malpractice; and (iii) for acts of negligence from July 1, 2019 and forward, \$1,800 and annual aggregate claims to \$15,000 of which up to \$1,300 would be paid by the Fund and \$500 by the Indiana University Health System for each occurrence of malpractice. The Act also requires that health care providers meet certain requirements, including making funding payments to the Fund and maintaining certain insurance levels. The Indiana University Health System has met these requirements and is a qualified provider under the Act, retaining risk of \$250 per occurrence and \$7,500 in the annual aggregate for acts of negligence occurring prior to June 30, 2017; \$400 per occurrence and \$12,000 in the annual aggregate for acts of negligence occurring from July 1, 2017 to June 30, 2019; and \$500 per occurrence and \$15,000 in the annual aggregate for acts of negligence occurring from July 1, 2019 forward. Indiana University Health System's medical malpractice program includes coverage offered by IUHRRG and reinsured by IUH Assurance SPC, Ltd. (IUHAL), a wholly owned subsidiary. This reinsurance also serves as excess insurance for general liability, automobile liability, IUHAL helipad, nonowned aircraft, employer's liability, managed care errors and omissions, and professional liability. This coverage is provided on a claims-made basis (aggregating \$70,000 as of July 1, 2014 and forward, and \$100,000 prior).

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

### 14. Medical Malpractice (continued)

Contributions for coverage provided by the captive insurance companies are expensed as incurred, and loss reserves are established for incurred but not yet reported claims. Laws in the jurisdictions in which the captive insurance companies are domiciled require, among other matters, that certain capital and funding requirements be met. The actuarially determined amount of accrued medical malpractice claims is included in noncurrent liabilities on the accompanying consolidated balance sheets.

#### 15. Retirement Plans

Retirement benefits are provided to substantially all employees of the Indiana University Health System, primarily through defined contribution plans. Contributions to the defined contribution plans, which are included in salaries, wages, and benefits on the consolidated statements of operations and changes in net assets, are based on compensation of qualified employees and amounted to \$119,687 and \$105,160 in 2022 and 2021, respectively (net of forfeitures of \$1,753 and \$1,637 in 2022 and 2021, respectively).

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

### 16. Functional Expenses

The tables below present expenses by both their nature and function for the years ended December 31, 2022 and 2021.

	Health Services	Insurance Services	eneral and ministrative	Total
Year ended December 31, 2022:				
Salaries, wages, and benefits	\$ 4,397,218	\$ 32,638	\$ 139,095	\$ 4,568,951
Supplies, drugs, purchased				
services, and other	2,480,277	58,176	168,203	2,706,656
Hospital assessment fee	206,632	-	_	206,632
Health claims to providers	_	130,407	_	130,407
Depreciation and amortization	286,637	_	16,814	303,451
Interest	49,305	_	_	49,305
	\$ 7,420,069	\$ 221,221	\$ 324,112	\$ 7,965,402

	Health	Insurance	General and	
	Services	Services	Administrative	Total
Year ended December 31, 2021:				
Salaries, wages, and benefits	\$ 3,859,559	\$ 31,862	\$ 129,578	\$ 4,020,999
Supplies, drugs, purchased				
services, and other	2,338,722	79,751	205,505	2,623,978
Contribution to related entity	416,000	-	_	416,000
Hospital assessment fee	185,979	_	_	185,979
Health claims to providers	_	146,271	_	146,271
Depreciation and amortization	267,306	_	12,127	279,433
Interest	35,832	_	-	35,832
	\$ 7,103,398	\$ 257,884	\$ 347,210	\$ 7,708,492

The consolidated financial statements report certain categories of expenses that are attributable to more than one supporting function. Therefore, these expenses require allocation on a reasonable basis that is consistently applied. The expenses that are allocated include salaries, wages, and benefits, which are allocated on a per full-time equivalent basis.

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

### 17. Related-Party Transactions

#### Indiana University School of Medicine

The Consolidation Agreement requires that Indiana University Health fund salaries and related employee benefit costs for medical doctor interns and residents of the School of Medicine who provide services at the Indiana University Health System's facilities. These costs totaled \$48,410 and \$48,166 in 2022 and 2021, respectively, and have been reported within salaries, wages, and benefits expense on the accompanying consolidated statements of operations and changes in net assets.

The Indiana University Health System purchases certain services from the School of Medicine. These expenses, principally for certain physician and staff salaries, medical directors, medical care case management services, utilities, laboratory services, and other services, totaled \$60,420 and \$59,725, net of offsetting funds from the School of Medicine, for the years ended December 31, 2022 and 2021, respectively, and have been reported within salaries, wages, and benefits and supplies, drugs, purchased services, and other expenses on the accompanying consolidated statements of operations and changes in net assets.

The Indiana University Health System also provides additional support to the School of Medicine to assist with medical education and research. During 2022 and 2021, Indiana University Health expensed \$3,717 and \$65,686, respectively, within supplies, drugs, purchased services, and other expenses on the accompanying consolidated statements of operations and changes in net assets.

Additionally, in 2012, Indiana University Health committed \$75,000 to support for a five-year period through December 31, 2016, certain basic, clinical, and translational research programs of the School of Medicine. In 2017, a new five-year term of \$55,000 was agreed upon effective July 1, 2017 through June 30, 2022. In December 2021, the agreement was amended to expire early, at the end of 2021. For the year ended December 31, 2021, the Indiana University Health System expensed \$17,000 under these agreements within supplies, drugs, purchased services, and other expenses on the accompanying consolidated statement of operations and changes in net assets.

On December 9, 2021, the Indiana University Health, Inc. Board of Directors approved a onetime contribution to the Indiana University School of Medicine. Indiana University Health provided the Indiana University School of Medicine an unrestricted contribution of \$416,000,

# Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

### 17. Related-Party Transactions (continued)

with \$400,000 supporting the education and research mission of the Indiana University School of Medicine, including recruitment, diversity, equity, and inclusion; \$16,000 was specifically designated for the Indiana University School of Nursing. The contribution was paid on December 30, 2021, and was recorded as contribution to related entity on the consolidated statement of operations and changes in net assets for the year ended December 31, 2021.

#### Other Foundations

As a commitment to continued support of educational and research efforts, Indiana University Health recognized contributions of \$29,019 and \$24,361 for the years ended December 31, 2022 and 2021, respectively, to the Indiana University Medical Group Foundation. The contributions were recorded as supplies, drugs, purchased services, and other expenses on the accompanying consolidated statements of operations and changes in net assets. The contributions serve to enhance current teaching programs and ultimately the access to high-quality medical care.

Tipton County Foundation is a tax-exempt organization under Section 501(c)(3) of the IRC; this foundation holds funds solely on behalf of Tipton Hospital. The financial statements of this foundation are not included in the consolidated financial statements. The interests in net assets of this and other foundations, which totaled \$15,737 and \$15,820 at December 31, 2022 and 2021, respectively, are included within interests in net assets of unconsolidated foundations on the accompanying consolidated balance sheets and principally represent donor-restricted funds.

These foundations also hold other net assets that are subject to the direction of their respective boards of directors. Other changes in the net assets of these foundations are generally reflected within temporarily and permanently restricted net assets.

#### 18. Health Care Legislation and Regulation

The health care industry is subject to numerous laws and regulations of federal, state, and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure; accreditation; participation requirements; reimbursement for patient services; Medicare and Medicaid fraud and abuse; and security, privacy, and

## Notes to Consolidated Financial Statements (continued) (Thousands of Dollars)

### 18. Health Care Legislation and Regulation (continued)

standards of health information. Government activity has continued with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and noncompliance with regulations by health care providers. Violations of these laws and regulations could result in expulsion from government health care programs together with the imposition of significant fines and penalties, significant repayments for patient services previously billed, and disruptions or delays in processing administrative transactions, including the adjudication of claims and payment.

In the opinion of management, there are no known regulatory inquiries that are expected to have a material adverse effect on the consolidated financial statements of the Indiana University Health System; however, compliance with such laws and regulations can be subject to future government review and interpretation, as well as regulatory actions unknown or unasserted at this time.

During the COVID-19 pandemic, the rate of Americans without health insurance dropped to a near-historic low in response to various federal initiatives connected to the federally declared Public Health Emergency (PHE). However, on February 9, 2023, U.S. Department of Health and Human Services Secretary Becerra sent a letter to U.S. governors informing them that effective February 11, 2023, he is renewing the PHE for 90 days and this is anticipated to be the last renewal. In the meantime, states are already taking the necessary steps to commence Medicaid redeterminations, which can begin as early as April 1, 2023 pursuant to the Congressional Omnibus package signed into law late last year. Providers and patient advocacy groups continue to express that millions of low-income and middle-income Americans will be at risk of losing health insurance once states begin the process of Medicaid redeterminations. In fact, the State of Indiana estimates that approximately 375,000 Hoosiers could be disenrolled or downgraded to less comprehensive benefits as a result of redeterminations.

#### **EY** | Building a better working world

EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets.

Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.

Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

© 2023 Ernst & Young LLP. All Rights Reserved.

ey.com